Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

(section 4)

Part 2 – Table 1

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
728	BACKHOUSIA CITRIODORA	A, E, H	The herbal substance must be derived from leaf oil only. Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10g/kg or 10g/L or 1%. The medicine requires the following warning statements on the medicine label: - (IRRIT) 'If irritation develops - discontinue use' - (CHILD3) 'Use in children under 12 years is not recommended' - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
729	BACOPA MONNIERI	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
730	BALLOTA NIGRA	A, H	
731	BALM OF GILEAD BUD DRY	A, H	
732	BALM OF GILEAD BUD POWDER	A, H	
733	BALSAM COPAIBA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
734	BAMBUSA BREVIFLORA	A, E, H	
735	BAMBUSA TEXTILIS	A, H	
736	BANANA	E	
737	BANANA DISTILLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
738	BAPTISIA CONFUSA	A, H	
739	BAPTISIA TINCTORIA	A, H	
740	BARBAREA VULGARIS	A, H	
741	BARIUM CARBONATE	H	Only for use as an active

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			homoeopathic ingredient.
742	BARIUM CHLORIDE	H	Only for use as an active homoeopathic ingredient.
743	BARIUM SULFATE	E	Only for use in topical medicines for dermal application.
744	BARLEY	E	Gluten is a mandatory component of Barley when the route of administration is other than topical and mucosal. When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
745	BARLEY BRAN	E	Gluten is a mandatory component of Barley bran when the route of administration is other than topical and mucosal. When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
746	BARLEY GERM	E	Gluten is a mandatory component of Barley germ when the route of administration is other than topical and mucosal. When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
747	BARLEY LEAF	E	
748	BASIC BUTYLATED METHACRYLATE COPOLYMER	E	Only for use in oral medicines.
749	BASIC FUCHSIN	E	Only for use as a colour ingredient in topical medicines for dermal application.
750	BASIC RED 1	E	Only for use as a colour in topical medicines for dermal application and not to be included in medicines

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%.
751	BASIC VIOLET 11:1	E	Only for use as a colour in topical medicines for dermal application and not intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%.
752	BASIL OIL COMOROS	A, E, H	Methyl chavicol is a mandatory component of Basil oil Comoros. When the concentration of Methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL. When the concentration of Methyl chavicol in the medicine is more than 5% and the nominal capacity of the container is 25mL or less, a restricted flow insert must fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
753	BASIL OIL EUROPEAN	A, E, H	Methyl chavicol is a mandatory component of Basil oil European. When the concentration of Methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL. When the concentration of Methyl chavicol in the medicine is more than 5% and the nominal capacity of the container is 25mL or less, a restricted flow insert must fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
754	BASSIA SCOPARIA	A, H	
755	BATYL ALCOHOL	E	Only for use in topical medicines for dermal application.
756	BAY LEAF	E	
757	BAY OIL	A, E, H	When the concentration of Bay oil in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			When the concentration of Bay oil in the medicine is more than 25% and the nominal capacity of the container is no more than 15 mL, there must be a restricted flow insert fitted on the container. When the concentration of Bay oil in the medicine is more than 25% and the nominal capacity of the container is more than 15 mL, a child resistant closure and restricted flow insert must be fitted on the container. The medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or word to that effect) - (NTAKEN) 'Not to be taken'
758	BEESWAX ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
759	BEET RED	E	Permitted for use only as a colour for oral and topical use.
760	BEETROOT	E, H	
761	BEGONIA FIMBRISTIPULA	A, H	
762	BEHENETH-10	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1.5%. Residual levels of ethylene oxide are to be kept below the level of detection.
763	BEHENIC ACID	E	When for oral ingestion, the maximum recommended daily dose must not provide more than 383.5 milligrams of behenic acid.
764	BEHENOXY DIMETHICONE	E	Only for use in topical medicines for dermal application.
765	BEHENOYL STEARIC ACID	E	Only for use in topical medicines for dermal application and not to be included in topical medicines

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			intended for use in the eye. The concentration in the medicine must be no more than 2.4%.
766	BEHENYL ALCOHOL	E	Only for use in topical medicines for dermal application.
767	BELLADONNA HERB DRY	A, H	Alkaloids calculated as hyoscyamine and atropine are mandatory components of Belladonna herb dry. The concentration of alkaloids calculated as hyoscyamine in the medicine and must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of atropine in the medicine must be no more than 100 micrograms/kg or 100 micrograms/L or 0.00001%.
768	BELLADONNA HERB POWDER	A, H	Alkaloids calculated as hyoscyamine and atropine are mandatory components of Belladonna herb powder. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			micrograms/L or 0.00003%. The concentration of atropinei n the medicine must be no more than 100 micrograms/kg or 100 micrograms/L or 0.00001%.
769	BELLADONNA HERB PREPARED	A, H	Alkaloids calculated as hyoscyamine and atropine are mandatory components of Belladonna herb prepared and must be declared in the application. The concentration of alkaloids calculated as hyoscyamine from all ingredients in the product must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of atropine from all ingredients in the product must be no more than 100 micrograms/kg or 100 micrograms/L or 0.00001%.
770	BELLIS PERENNIS	A, H	
771	BEMOTRIZINOL	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%. When used in primary sunscreen

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
772	BENINCASA HISPIDA	A, E, H	
773	BENTONITE	E	
774	BENZALDEHYDE	E	
775	BENZALDEHYDE GLYCERYL	E	Permitted for use only in combination with other permitted

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	ACETAL		ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
776	BENZALKONIUM CHLORIDE	E	Only for use in topical medicines for dermal application and nasal sprays. The concentration in the medicine must be no more than 5%.
777	BENZETHONIUM CHLORIDE	E	Only for use as a preservative in topical medicines for dermal application. The medicine requires the warning statement: - (BNZTHC) 'Contains Benzethonium chloride' (or words to that effect).
778	BENZOIC ACID	E, H	Medicines containing benzoates require the following warning statement on the medicine label: - (TBNZO8) ‘Contains benzoates' (or words to this effect)’ if the medicine contains two or more benzoate sources or ‘Contains [insert the approved name of benzoate used] (or words to this

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			effect)' if product contains one benzoate source.
779	BENZOIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
780	BENZOIN SIAM	A, E, H	
781	BENZOIN SUMATRA	A, E, H	
782	BENZOPHENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
783	BENZYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
784	BENZYL ACETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as a fragrance the total fragrance concentration in a medicine must be no more than 1%.
785	BENZYL ALCOHOL	E	The medicine requires the warning statement: - (BNZALC) 'Contains benzyl alcohol [quantity]' (or words to that effect).
786	BENZYL BENZOATE	E	Only for use in topical medicines for dermal application. Medicines containing benzoates require the warning statement: - (TBNZO8) 'Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate used]' (or words to this

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			effect) if product contains one benzoate source.
787	BENZYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
788	BENZYL CINNAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.15%.
789	BENZYL DIMETHYL CARBINYL-N-BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
790	BENZYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
791	BENZYL ISOAMYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
792	BENZYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
793	BENZYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
794	BENZYL LAURATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
795	BENZYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
796	BENZYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
797	BENZYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
798	BENZYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
799	BENZYLIDENE ACETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
800	BENZYLIDENE CAMPHOR SULFONIC ACID	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 6% (as acid). When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
801	BERBERIS AQUIFOLIUM	A, H	
802	BERBERIS ARISTATA	A	Only for use in oral medicines. The medicine requires the following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
803	BERBERIS VULGARIS	A, E, H	
804	BERGAMOT OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour, the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%. If used in a fragrance, the total fragrance concentration in a medicine must be no more 1%. The medicine requires the following warning statement on the medicine label: - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect)
805	BERGAMOT OIL BERGAPTEN-FREE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
806	BERGAMOT OIL COLDPRESSED	A, E, H	When for internal use oxedrine is a mandatory component of bergamot oil coldpressed. The maximum recommended daily dose must provide no more than 30 milligrams of oxedrine.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 0.4 per cent or less of bergamot oil coldpressed; or c) for use in soaps or bath or shower gels that are washed off the skin.
807	BERGAMOT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
808	BERTHOLLETIA EXCELSA	A, E, H	
809	BETA RAPA	A, E, H	
810	BETA VULGARIS	A, E, H	
811	BETA,4-DIMETHYLCYCLOHEX-3-ENE-1-PROPAN-1-AL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			fragrance concentration in a medicine must be no more than 1%.
812	BETA-CARYOPHYLLENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
813	BETA-CARYOPHYLLENE ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
814	BETA-DAMASCENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
815	BETA-DAMASCONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
816	BETA-HOMO CYCLOCITRAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
817	BETA-HYDROXY-BETA-METHYLBUTYRIC ACID	A	
818	BETA-IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
819	BETA-IONONE EPOXIDE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
820	BETA-ISO-METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
821	BETA-METHYL NAPHTHYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
822	BETA-N-METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
823	BETA-NAPHTHOL ETHYLETHER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
824	BETA-NAPHTHOL METHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
825	BETA-NAPHTHYL ANTHRANILATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
826	BETA-NAPHTHYL ISOBUTYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
827	BETA-PINENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
828	BETA-TOCOPHEROL	E	
829	BETACAROTENE	A, E	When Vitamin A is declared as an equivalent of Betacarotene and the medicine is for oral or sublingual use in adults the medicine requires the following warning statement on the medicine label: - (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
830	BETADEX	E	
831	BETAGLUCAN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.01%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
832	BETAINE	E	Only for use in topical medicines for dermal application.
833	BETAINE HYDROCHLORIDE	E	
834	BETULA LENTA	A, H	Methyl salicylate is a mandatory component of Betula lenta. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.
835	BETULA NIGRA	A, H	Cresol, eugenol and methyl salicylate are mandatory components of Betula nigra. For external use only when the total concentration of cresols, xylenols and other phenol homologues in the medicine is greater than 3%. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine requires child resistant packaging.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.
836	BETULA PENDULA	A, E, H	Methyl salicylate is a mandatory component of Betula pendula. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.
837	BETULA PUBESCENS	A, E, H	
838	BICYCLO(2.2.1)HEPT-5-ENE-2-CARBOXYLIC ACID, 3-(1-METHYLETHYL)-, ETHYL ESTER, (1R,2R,3R,4S)-REL-	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
839	BICYCLO(2.2.2)OCT-5-ENE-2-CARBOXALDEHYDE, 6-METHYL-8-(1-METHYLETHYL)-	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
840	BIFIDOBACTERIUM ADOLESCENTIS	A	
841	BIFIDOBACTERIUM ANIMALIS	A	
842	BIFIDOBACTERIUM ANIMALIS SSP ANIMALIS	A	
843	BIFIDOBACTERIUM ANIMALIS SSP LACTIS	A	
844	BIFIDOBACTERIUM BIFIDUM	A	
845	BIFIDOBACTERIUM BREVE	A	
846	BIFIDOBACTERIUM INFANTIS	A	
847	BIFIDOBACTERIUM LACTIS	A	
848	BIFIDOBACTERIUM LONGUM	A	
849	BILBERRY	E	
850	BIOSACCHARIDE GUM-1	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
851	BIOTA ORIENTALIS	A, H	
852	BIOTIN	A, E	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
853	BIRCH LEAF DRY	A, E, H	Methyl salicylate is a mandatory component of Birch leaf dry. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
854	BIRCH TAR OIL RECTIFIED	A, E, H	Cresol is a mandatory component of birch tar oil rectified. For external use only when the total concentration of cresols, xylenols and other phenol homologues in the medicine is greater than 3%.
855	BIS-DIGLYCERYL POLYACYLADIPATE-2	E	Only for use in topical medicines for dermal application.
856	BIS-ETHYLHEXYL HYDROXYDIMETHOXY BENZYLMALONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
857	BIS-MACROGOL 900 METHYL ETHER DIMETHYL SILANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2.5%.
858	BIS-PEG-12 DIMETHICONE BEESWAX	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			The concentration in the medicine must be no more than 0.2%.
859	BIS-STEARYL ETHYLENEDIAMINE/NEOPENTYL GLYCOL/STEARYL HYDROGENATED DIMER DILINOLEATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
860	BISABOLENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
861	BISABOLOL	E	If used as an excipient, the medicine is only for use in topical medicines for dermal application.
862	BITTER ALMOND OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. The absence of amygdalin in the medicine must be declared.
863	BIXA ORELLANA	A, E, H	
864	BLACK BONED CHICKEN POWDER	A	
865	BLACK COHOSH DRY	A, H	The medicine requires the following warning statement on the medicine label: - (BCOHOSH) 'Warning: In very rare cases - black cohosh has been associated with liver failure. If you are experiencing yellowing of the skin or whites of the eyes - dark urine - nausea - vomiting - unusual tiredness - weakness - stomach or abdominal pain - and/or loss of appetite - you should stop using this product and see your doctor.'
866	BLACK COHOSH POWDER	A, H	The medicine requires the following warning statement on the medicine label: - (BCOHOSH) 'Warning: In very rare cases - black cohosh has been associated with liver failure. If you are experiencing yellowing of the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			skin or whites of the eyes - dark urine - nausea - vomiting - unusual tiredness - weakness - stomach or abdominal pain - and/or loss of appetite - you should stop using this product and see your doctor.'
867	BLACK CURRANT	E	
868	BLACK CURRANT ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
869	BLACK CURRANT FRESH	A, E, H	
870	BLACK CURRANT SEED OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
871	BLACK OF CURACAO SPIDER	H	Only for use as an active

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			homoeopathic ingredient.
872	BLACK PEPPER OIL	A, E, H	
873	BLACK RASPBERRY	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
874	BLACK SNAKE	H	Only for use as an active homoeopathic ingredient.
875	BLACKBERRY	E	
876	BLACKBERRY OILS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
877	BLACKBERRY WINE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%.
878	BLACKCURRANT ESTERS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
879	BLACKCURRANT JUICE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
880	BLACKSTRAP MOLASSES	E	When for oral or sublingual use, Sucrose is a mandatory component of Molasses - blackstrap. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
881	BLADDERWRACK DRY	A, H	Iodine is a mandatory component of Bladderwrack dry. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
882	BLADDERWRACK POWDER	A, H	Iodine is a mandatory component of Bladderwrack powder. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
883	BLAINVILLEA ACMELLA	A, E, H	When used as an excipient, permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
884	BLETILLA STRIATA	A, H	
885	BLUE FLAG RHIZOME DRY	A, H	
886	BLUE FLAG RHIZOME POWDER	A, H	
887	BLUEBERRY	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
888	BLUEBERRY JUICE	E	Permitted for use only in combination with other permitted ingredients as a flavour or

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
889	BLUMEA LACERA	A, H	
890	BOEHMERIA NIVEA	A, H	
891	BOERHAVIA DIFFUSA	A, H	
892	BOERHAVIA REPENS	A, H	
893	BOGBEAN LEAF DRY	A, H	
894	BOGBEAN LEAF POWDER	A, H	
895	BOIS DE ROSE OIL	A, E, H	
896	BOMBAX CEIBA	A, H	
897	BORAGO OFFICINALIS	A, E, H	Only for use when the preparation is 'fixed oil' and the fixed oil is derived from seeds of Borago officinalis.
898	BORAX	A, E, H	Boron is a mandatory component of Borax. The percentage of Boron from Borax should be calculated based

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			on the molecular weight of Borax. The maximum recommended daily dose must provide no more than 6mg of Boron. In preparations for dermal use, which are not for paediatric or antifungal use, the concentration of Boron in the medicine must be no more than 3500 mg/kg or 3500 mg/L or 0.35%.
899	BORAX PENTAHYDRATE	A, E	Boron is a mandatory component of Borax Pentahydrate. The percentage of Boron from Borax pentahydrate should be calculated based on the molecular weight of Borax Pentahydrate. The maximum recommended daily dose must provide no more than 6mg of Boron from Borax pentahydrate. In preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron in the medicine must be no more than 3500 mg/kg or 3500 g/L or 0.35%.
900	BORIC ACID	A, H	Boron is a mandatory component of Boric acid.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The percentage of Boron from Boric acid should be calculated based on the molecular weight of Boric acid. The maximum recommended daily dose must provide no more than 6mg of Boron. In preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron in the medicine must be no more than 3500 mg/kg or 3500 mg/L or 0.35%.
901	BORNEOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
902	BORNYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			medicine must be no more than 1%.
903	BORON NITRIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
904	BORONIA ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
905	BORONIA MEGASTIGMA	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
906	BOSWELLIA CARTERII	A, E, H	
907	BOSWELLIA SERRATA	A, E, H	
908	BOSWELLIA THURIFERA	A, H	
909	BOVINE CALCIUM CHONDROITIN SULFATE	A	
910	BOVINE CHONDROITIN SULFATE	A	
911	BOVINE COLOSTRUM POWDER	A	The medicine requires the warning statement: - (BOVCOL) 'Products containing bovine colostrum powder contain lactose and cow's milk proteins (or words to that effect). This product is not suitable for use in children under the age of 12 months except on professional health advice.'
912	BOVINE LACTOFERRIN	A	The medicine requires the following warning statement on the medicine label: - (COWMK) 'Derived from cow's milk.'
913	BOVINE POTASSIUM CHONDROITIN SULFATE	A	
914	BOVINE SODIUM CHONDROITIN SULFATE	A	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
915	BOVINE WHEY IG-RICH FRACTION	A	Only for use in oral medicines. The medicine requires the following warning statements on the medicine label: - (COWMK) 'Derived from cows milk' - (BABY3) 'Not suitable for use in children under the age of 12 months - except on the advice of a health professional)'.
916	BRANDY	E	
917	BRASSICA CHINENSIS	A, H	Allyl isothiocyanate is a mandatory component of Brassica chinensis when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
918	BRASSICA JUNCEA	A, H	Allyl isothiocyanate is a mandatory component of Brassica juncea when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
919	BRASSICA NAPUS	A, E, H	Allyl isothiocyanate is a mandatory component of Brassica napus when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
920	BRASSICA NIGRA	A, H	Allyl isothiocyanate is a mandatory component of Brassica nigra when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
921	BRASSICA OLERACEA VAR. BOTRYTIS	A, E, H	Allyl isothiocyanate is a mandatory component of Brassica oleracea var. botrytis when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
922	BRASSICA OLERACEA VAR. CAPITATA	A, E, H	Allyl isothiocyanate is a mandatory component of Brassica oleracea var. capitata when the plant part is seed. The concentration of allyl

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
923	BRASSICA OLERACEA VAR. GEMMIFERA	A, H	Allyl isothiocyanate is a mandatory component of Brassica oleracea var gemmifera when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
924	BRASSICA OLERACEA VAR. ITALICA	A, H	Allyl isothiocyanate is a mandatory component of Brassica oleracea var. italica when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
925	BRASSICA OLERACEA VAR. VIRIDIS	A, H	Allyl isothiocyanate is a mandatory component of Brassica oleracea var. viridis when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
926	BRASSICA PEKINENSIS	A, H	Allyl isothiocyanate is a mandatory component of Brassica pekinensis when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
927	BRASSICA RAPA	A, E, H	Allyl isothiocyanate is a mandatory component of Brassica rapa when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
928	BRAZIL NUT	E	
929	BRILLIANT BLACK BN	E	Permitted for use only as a colour for oral and topical use.
930	BRILLIANT BLUE FCF	E	Permitted for use only as a colour for oral and topical use.
931	BRILLIANT BLUE FCF ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
932	BRILLIANT BLUE FCF BARIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
933	BRILLIANT SCARLET 4R	E	Permitted for use only as a colour for oral and topical use.
934	BRILLIANT SCARLET 4R ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
935	BRIZA MEDIA	A, H	
936	BROCCOLI	E	
937	BROMELAINS	A	May be derived from either the stem or fruit of the pineapple (Ananas comosus). If used in a divided preparation, the allowed units are papain units and million papain units. If used in an undivided preparation, the allowed units are million papain units per gram.
938	BROMINE	H	Only for use as an active homoeopathic ingredient. The concentration of bromine in the preparation must be no more than 14mg/Kg or 14mg/L or 0.0014%

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			for oral and sublingual use.
939	BROMOSTYROL	E	Not for use in infants Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
940	BROMUS CATHARTICUS	A, H	
941	BROMUS INERMIS	A, H	
942	BROMUS RAMOSUS SUBSP. RAMOSUS	A, H	
943	BRONOPOL	E	Only for use as an excipient in topical medicines for dermal application. The medicine requires the warning statement: - (BRONOP) 'Contains bronopol [quantity]' (or words to that effect).
944	BROUSSONETIA PAPYRIFERA	A, H	
945	BROWN FK	E	Permitted for use only as a colour for topical use.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
946	BRUNFELSIA UNIFLORA	A, H	The maximum daily dose must be no more than the equivalent of 1mg of the dry herbal material.
947	BRUSSEL SPROUT	E	
948	BRYONIA ALBA	A, H	
949	BRYONIA DIOICA	A, H	
950	BUCHU LEAF DRY	A, H	
951	BUCHU LEAF OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
952	BUCHU LEAF POWDER	A, E, H	
953	BUCKWHEAT	E, H	Only for use as an active homoeopathic or excipient ingredient.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
954	BUDDLEJA OFFICINALIS	A, H	
955	BULNESIA SARMIENTI	A, E, H	
956	BUNIAS ORIENTALIS	A, H	
957	BUPLEURUM FALCATUM	A, H	
958	BURDOCK LEAF DRY	A, H	
959	BURDOCK LEAF POWDER	A, H	
960	BURDOCK ROOT DRY	A, H	
961	BURDOCK ROOT POWDER	A, H	
962	BUSHMASTER SNAKE	H	Only for use as an active homoeopathic ingredient.
963	BUTAN-1-OL	E	The residual solvent limit for Butan-1-ol is 50 mg per maximum recommended daily dose. The concentration in the medicine must be no more than 0.5%.
964	BUTANE	E	Only for use as an excipient propellant ingredient.
965	BUTOXYETHANOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			must be no more than 0.1%.
966	BUTTER	E	
967	BUTTER ACIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
968	BUTTER ESTERS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
969	BUTTER STARTER DISTILLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
970	BUTYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
971	BUTYL ACETATE	E	The residual solvent limit for Butyl acetate is 50 mg per maximum recommended daily dose. The concentration in the medicine must be no more than 0.5%.
972	BUTYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
973	BUTYL BUTYRYL LACTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
974	BUTYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
975	BUTYL ESTER OF PVM/MA COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 15%. The medicine requires the following warning statements on the medicine label: - (EYE) 'Avoid contact with eyes' (or words to that effect) - (EYE2) 'May be irritant to the eyes' (or words to that effect).
976	BUTYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
977	BUTYL HYDROXYBENZOATE	E	Only for use in topical medicines for dermal application. Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
978	BUTYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
979	BUTYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
980	BUTYL LACTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
981	BUTYL LEVULINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
982	BUTYL METHOXYDIBENZOYLMETHANE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in preparation must be no more than 5%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
983	BUTYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
984	BUTYL STEARATE	E	Only for use in topical medicines for dermal application.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
985	BUTYL UNDECYLENATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
986	BUTYLATED HYDROXYANISOLE	E	When used as an antimicrobial preservative, the medicine requires the warning statement: - (BHANIS) 'Contains butylated hydroxyanisole' (or words to that effect).
987	BUTYLATED HYDROXYTOLUENE	E	
988	BUTYLENE GLYCOL DICAPRYLATE/DICAPRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
989	BUTYLIDENE PHTHALIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
990	BUTYLOCTYL SALICYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
991	BUTYLPHENYL METHYLPROPIONAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
992	BUTYRALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
993	BUTYRIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
994	C1-8 ALKYL TETRAHYDROXYCYCLOHEXANOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.012%.
995	C10-12 ALKANE/CYCLOALKANE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
996	C10-30 CHOLESTEROL/LANOSTEROL ESTERS	E	Only for use in topical medicines for dermal application.
997	C11-14-ISO-ALCOHOL C-13 RICH	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
998	C12-13 PARETH-23	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.125%. Residual levels of 1,4-dioxane and ethylene oxide (and related substances) are to be kept below the level of detection.
999	C12-13 PARETH-3	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.125%. Residual levels of 1,4-dioxane and ethylene oxide (and related

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			substances) are to be kept below the level of detection.
1000	C12-15 ALKYL LACTATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
1001	C12-15 ALKYL OCTANOATE	E	Only for use in topical medicines for dermal application.
1002	C12-20 ACID PEG-8 ESTER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.2%.
1003	C12-20 ALKYL GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.75%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1004	C13-14 ISOPARAFFIN	E	Only for use in topical medicines for dermal application.
1005	C14-22 ALCOHOLS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2.55%.
1006	C15-19 ALKANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
1007	C18-36 ACID GLYCOL ESTER	E	Only for use topical medicines for dermal application.
1008	C18-36 ACID TRIGLYCERIDE	E	Only for use in topical medicines for dermal application.
1009	C2-OCTENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
1010	C20-40 ALCOHOLS	E	Only for use in topical medicines for dermal application.
1011	C20-40 ALKYL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.
1012	C20-40 PARETH-24	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.25%.
1013	C20-40 PARETH-3	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1014	C30-45 ALKYL CETEARYL DIMETICONE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
1015	C9-11 ISOPARAFFIN	E	Only for use in topical medicines for dermal application.
1016	C9-11 PARETH-3	E	Only for use in topical medicines for dermal application.
1017	C9-15 ALKYL PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.12%
1018	CABBAGE	E	
1019	CABREUVA OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1020	CADE OIL	A, E, H	
1021	CAESALPINIA SAPPAN	A, H	
1022	CAFFEINE	A, E	When used as an excipient, only for use in topical medicines for dermal application. Only for use as an active ingredient for oral use in adults when the medicine consists principally of one or more designated active ingredients prescribed in Schedule 14 to the Regulations (other than caffeine); and contains no more than 100 mg of caffeine per maximum daily dose. Medicines for oral use containing caffeine as an active ingredient require the following warning statement on the medicine label: - (ADULT) 'Adults only' (or words to that effect). When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFFR) 'The recommended dose

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1023	CAJUPUT OIL	A, E, H	Cineole is a mandatory component of Cajuput oil. When the concentration in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL. When the concentration in the medicine is more than 25% and the nominal capacity of the container is more than 15 mL, a child resistant closure and restricted flow insert must be fitted on the container. When the concentration in the medicine is more than 25% and the nominal capacity of the container is less than 15 mL, a restricted flow insert must be fitted to the container. When the concentration in the medicine is more than 25%, the medicine requires the following

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or word to that effect) - (NTAKEN) 'Not to be taken'. When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 mL. When the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL but no more than 25mL, the medicine must have a child resistant closure and restricted flow insert fitted on the container and the medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or word to that effect) - (NTAKEN) 'Not to be taken'. When the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 mL, the medicine must have the restricted flow insert fitted on the container and the medicine requires the following warning statements

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			on the medicine label: - (CHILD) 'Keep out of reach of children' (or word to that effect) - (NTAKEN) 'Not to be taken'.
1024	CALAMINE	A, E	Only for use as an active or excipient ingredient for dermal application. When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
1025	CALCIFIED LITHOTHAMNION SPECIES	A	Only for use in oral medicines.
1026	CALCIFIED LITHOTHAMNION TOPHIFORME	A	Only for oral use.
1027	CALCIUM ALGINATE	E	
1028	CALCIUM AMINO ACID CHELATE	A, H	Calcium is a mandatory component of calcium amino acid chelate. The concentration of calcium in the calcium amino acid chelate must be no more than 25% w/w.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1029	CALCIUM ASCORBATE	A, E, H	
1030	CALCIUM ASCORBATE DIHYDRATE	A, E, H	
1031	CALCIUM ASPARTATE	A	
1032	CALCIUM ASPARTATE HYDROCHLORIDE DIHYDRATE	A	Only for use in oral medicines.
1033	CALCIUM BEHENATE	E	Behenic acid is a mandatory component of Calcium behenate. When for oral ingestion, the maximum recommended daily dose must not provide more than 383.5 mg of Behenic acid.
1034	CALCIUM BETA-HYDROXY-BETA-METHYLBUTYRATE	A, H	
1035	CALCIUM BETA-HYDROXY-BETA-METHYLBUTYRATE MONOHYDRATE	A, H	
1036	CALCIUM CARBONATE	A, E, H	
1037	CALCIUM CASEINATE	E	
1038	CALCIUM CHLORIDE DIHYDRATE	E	
1039	CALCIUM CITRATE	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1040	CALCIUM CITRATE TETRAHYDRATE	A, E, H	
1041	CALCIUM DIASPARTATE	A	Only for use in oral medicines.
1042	CALCIUM FLUORIDE	H	The percentage of fluoride from Calcium fluoride should be calculated based on the molecular weight of Calcium fluoride. The concentration of fluoride in the product from all ingredients must be no more than 10mg/kg or 10mg/L or 0.1%.
1043	CALCIUM FOLINATE	A	Folinic acid is a mandatory component of calcium folinate. The maximum daily dose must provide no more than 500 micrograms of folinic acid. When folic acid, folinic acid, levomefolate salts and/or their derivatives are used in combination, the medicine provides not more than a total of 500 micrograms of folic acid, folinic acid, levomefolate salts and/or their derivatives in total per daily dose. When used in preparations indicated for reducing the risk of having a child with spina bifida/neural tube defects, the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			following statement must be included on the label: - (NEUR) 'Warning: Do not exceed the stated dose except on medical advice. If you have had a baby with a neural tube defect/spina bifida - seek specific medical advice (or words to that effect).'
1044	CALCIUM GLUCONATE MONOHYDRATE	A, E, H	
1045	CALCIUM GLYCEROPHOSPHATE	A, E, H	
1046	CALCIUM GLYCINATE	A	Only for use in oral medicines.
1047	CALCIUM GLYCINATE DIHYDRATE	A	
1048	CALCIUM HEXAFLUOROSILICATE	H	Only for use as an active homoeopathic ingredient.
1049	CALCIUM HYDROGEN PHOSPHATE	A, E, H	
1050	CALCIUM HYDROGEN PHOSPHATE DIHYDRATE	A, E, H	
1051	CALCIUM HYDROGEN PHOSPHATE MONOHYDRATE	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1052	CALCIUM HYDROXIDE	A, E, H	When used as a standard active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia as in force or existing from time to time.
1053	CALCIUM HYDROXYCITRATE	A, H	
1054	CALCIUM HYPOPHOSPHITE	H	Only for use as an active homoeopathic ingredient.
1055	CALCIUM IODIDE	H	Only for use as an active homoeopathic ingredient.
1056	CALCIUM KETOGLUCONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration must be no more than 1%
1057	CALCIUM L-THREONATE	A	Only for use in oral medicines.
1058	CALCIUM LACTATE	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1059	CALCIUM LACTATE GLUCONATE	A, E, H	
1060	CALCIUM LACTATE PENTAHYDRATE	A, E, H	
1061	CALCIUM LACTATE TRIHYDRATE	A, E, H	
1062	CALCIUM LYSINATE	A	Only for use in oral medicines.
1063	CALCIUM METHIONINATE	A	Only for use in oral medicines.
1064	CALCIUM OROTATE	A, E, H	
1065	CALCIUM OXIDE	E	Only for use in topical medicines for dermal application.
1066	CALCIUM PANTOTHENATE	A, E, H	
1067	CALCIUM PHOSPHATE	A, E, H	
1068	CALCIUM PYRUVATE	A	
1069	CALCIUM SACCHARATE	E	
1070	CALCIUM SILICATE	E	
1071	CALCIUM SODIUM CASEINATE	A, H	The medicine requires the following warning statement on the medicine label: - (COWMK) 'Derived from cow's milk'.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1072	CALCIUM SODIUM LACTATE	A, E, H	
1073	CALCIUM STEARATE	E	
1074	CALCIUM SUCCINATE	A, E, H	
1075	CALCIUM SULFATE	A, E, H	
1076	CALCIUM SULFATE DIHYDRATE	A, E, H	
1077	CALCIUM SULFIDE	H	Only for use as an active homoeopathic ingredient.
1078	CALCIUM THREONINATE	A	
1079	CALENDULA FLOWER DRY	A, E, H	
1080	CALENDULA FLOWER POWDER	A, H	
1081	CALENDULA OFFICINALIS	A, E, H	
1082	CALLERYA RETICULATA	A, H	
1083	CALLICARPA PEDUNCULATA	A, H	
1084	CALLISTEMON CITRINUS	A, H	
1085	CALLISTEPHUS CHINENSIS	A, H	
1086	CALLITRIS INTRATROPICA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
1087	CALLITRIS RHOMBOIDEA	A, H	
1088	CALLUNA VULGARIS	A, E, H	
1089	CALOCHORTUS TOLMIEI	A, H	
1090	CALTHA PALUSTRIS	A, H	
1091	CALUMBA ROOT DRY	A, H	
1092	CALUMBA ROOT POWDER	A, H	
1093	CALVATIA GIGANTEA	A, E, H	
1094	CALYCANTHUS FLORIDUS	A, H	
1095	CALYCANTHUS PRAECOX	A, H	
1096	CAMELLIA JAPONICA	A, H	
1097	CAMELLIA OLEIFERA	A, E, H	If Camellia oleifera (seed oil) is used as a solvent, it is restricted to topical or sunscreen preparations for dermal application only.
1098	CAMELLIA SINENSIS	A, E, H	Caffeine is a mandatory component of Camellia sinensis for oral use. Medicines for oral or sublingual administration that contain caffeine as a component of a herbal substance and that provide a maximum recommended daily dose

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			of: a) more than 1 mg but no more than 10 mg of caffeine require the following warning statement on the medicine label: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine require the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product].' Polyphenols calculated as gallic acid (of Camellia sinensis) is only permitted for use as a component when the plant part is leaf.
1099	CAMPHENE	E	Permitted for use only in combination with other permitted ingredients as a coating solution, a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1100	CAMPHOLENIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
1101	CAMPHOR	A, E, H	In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations, the concentration of camphor must be no more than 2.5%.
1102	CAMPHOR BENZALKONIUM METHOSULFATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the preparation must be no more than 6%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1103	CAMPHOR OIL BROWN	A, H	camphor, cineole and safrole are mandatory components of camphor oil brown. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%. In essential oil preparations, if the concentration of camphor is more

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres. When the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			the restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When for internal use then the concentration of safrole in a medicine must be no more than 0.1%. When for topical use then the concentration of safrole in a medicine must be no more than 1.0%. If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25mL.
1104	CAMPHOR OIL WHITE	A, E, H	Camphor and safrole are mandatory components of camphor oil white. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When for internal use then the concentration of safrole in a medicine must be no more than 0.1%. When for topical use then the concentration of safrole in a medicine must be no more than 1.0%. If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25mL.
1105	CAMPSIS GRANDIFLORA	A, H	
1106	CANADA BALSAM	A, H	
1107	CANANGA ODORATA	A, E, H	
1108	CANANGA OIL	A, E, H	
1109	CANARIUM INDICUM	A, H	The plant part must be seed and the plant preparation is oil.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The medicine requires the following warning statement on the medicine label: - (DERIVED) 'This product contains material derived from nuts' (or words to that effect).
1110	CANARIUM LUZONICUM	A, H	
1111	CANDELILLA WAX	A, E, H	
1112	CANDIDA ALBICANS	H	Only for use as an active homoeopathic ingredient.
1113	CANDIDA UTILIS	A, H	
1114	CANINE MILK	H	Only for use as an active homoeopathic ingredient.
1115	CANOLA OIL	A, E, H	Allyl isothiocyanate is a mandatory component of canola oil when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
1116	CANTHARIDES	H	Only available as an active homoeopathic ingredient.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1117	CANTHAXANTHIN	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1118	CAPRIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1119	CAPROIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1120	CAPRYLIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a coating solution, a

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1121	CAPRYLIC/CAPRIC GLYCERIDES	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1122	CAPRYLIC/CAPRIC/ISOSTEARIC /ADIPIC TRIGLYCERIDE	E	
1123	CAPRYLIC/CAPRIC/MYRISTIC/S TEARIC TRIGLYCERIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine is not to exceed 3%

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1124	CAPRYLIC/CAPRIC/STEARIC TRIGLYCERIDE	E	Only for use in topical medicines for dermal application.
1125	CAPRYLOYL GLYCINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 2%
1126	CAPRYLOYL SALICYLIC ACID	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must not be more than 0.3%.
1127	CAPRYLYL GLYCOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%
1128	CAPRYLYL METHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 10%.
1129	CAPSELLA BURSA-PASTORIS	A, H	
1130	CAPSICUM	E, H	Only for use as an active homoeopathic or excipient ingredient.
1131	CAPSICUM ANNUUM	A, E, H	
1132	CAPSICUM DRY	A, E, H	
1133	CAPSICUM FRUIT OLEORESIN	A, E	
1134	CAPSICUM FRUTESCENS	A, E, H	
1135	CAPSICUM POWDER	A, E, H	
1136	CARALLUMA ADSCENDENS VAR. FIMBRIATA	A	The plant part must be herb and the plant preparation must be a hydroethanolic extract.
1137	CARAMEL	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1138	CARAPICHEA IPECACUANHA	A, H	Emetine is a mandatory component of Carapichea ipecacuanha. The concentration of emetine in the medicine must be no more than 0.2%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			Except when used in a medicine containing only homoeopathic preparations, a child resistant closure must be fitted onto the container.
1139	CARAWAY DRY	A, H	
1140	CARAWAY OIL	A, E, H	
1141	CARAWAY POWDER	A, H	
1142	CARBOMER 1342	E	Only for use as an excipient in topical medicines for dermal application.
1143	CARBOMER 2001	E	Only for use as an excipient ingredient in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 1% in formulations at pH 7 (approximately neutral) and 0.1% in formulations at a different pH.
1144	CARBOMER 934	E	Only for use in topical medicines for dermal application.
1145	CARBOMER 934P	E	Only for use in topical medicines

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			for dermal application.
1146	CARBOMER 940	E	Only for use in topical medicines for dermal application.
1147	CARBOMER 941	E	Only for use as an excipient in topical medicines for dermal application.
1148	CARBOMER 954	E	Only for use as an excipient in topical medicines for dermal application.
1149	CARBOMER 980	E	Only for use as an excipient in topical medicines for dermal application.
1150	CARBOMER 981	E	Only for use as an excipient in topical medicines for dermal application.
1151	CARBOMER COPOLYMER (TYPE B)	E	Only for use as an excipient in topical medicines for dermal application.
1152	CARBOMER HOMOPOLYMER	E	Only for use as an excipient in

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	(TYPE B)		topical medicines for dermal application.
1153	CARBOMER U-10	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
1154	CARBON	E, H	Only for use as an active homoeopathic or excipient ingredient.
1155	CARBON BLACK	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1156	CARBON DIOXIDE	E	
1157	CARDAMOM FRUIT DRY	A, H	
1158	CARDAMOM FRUIT POWDER	A, E, H	
1159	CARDAMOM OIL	A, E, H	
1160	CARDIOSPERMUM HALICACABUM	A, H	
1161	CARICA PAPAYA	A, E, H	
1162	CARLINA ACAULIS	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1163	CARMELLOSE	E	
1164	CARMELLOSE CALCIUM	E	
1165	CARMELLOSE SODIUM	E	
1166	CARMINE	E	Permitted for use only as a colour for oral and topical use.
1167	CARMOISINE	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1168	CARMOISINE ALUMINIUM LAKE	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1169	CARNAUBA WAX	A, E, H	
1170	CARNOSINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.2%.
1171	CAROB BEAN EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1172	CAROB GUM	E	
1173	CAROB POD	E	
1174	CAROTENES	E	Permitted as an excipient ingredient as a colour for oral and topical use.
1175	CARPINUS BETULUS	A, H	
1176	CARPINUS CORDATA	A, H	
1177	CARRAGEENAN	E	
1178	CARROT	E	
1179	CARROT SEED OIL	A, E, H	
1180	CARTHAMUS TINCTORIUS	A, E, H	Carthamus tinctorius (sunflower oil) when used as a solvent is restricted to topical or sunscreen preparations for dermal application only. If for oral use, the medicine requires the following warning statement on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).
1181	CARUM CARVI	A, H	
1182	CARVACROL	E	Permitted for use only in

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1183	CARVACRYL METHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1184	CARVEOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1185	CARVONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1186	CARVYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1187	CARYA ILLINOINENSIS	A, H	
1188	CARYA OVATA	A, H	
1189	CARYOPHYLLENE OXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
1190	CASCARA DRY	A, H	Hydroxyanthracene derivatives calculated as cascaroside A is a mandatory component of Cascara dry when the route of administration is oral. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (LAX2) ‘Prolonged use may cause serious bowel problems’ - (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect) - (S) ‘If symptoms persist consult your healthcare practitioner' (or words to that effect). When promoted or marketed as a laxative, the medicine requires the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			following warning statement on the medicine label: - (LAX1) 'Drink plenty of water' (or words to that effect) When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]' - (LAX4) 'This product may have laxative effect' When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended' - (LAX1) 'Drink plenty of water' (or words to that effect) - (LAX2) 'Prolonged use may cause serious bowel problems' - (S) 'If symptoms persist consult your healthcare practitioner' (or words to that effect).

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1191	CASCARA POWDER	A, H	Hydroxyanthracene derivatives calculated as cascaroside A is a mandatory component of Cascara powder when the route of administration is oral administration. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (LAX2) ‘Prolonged use may cause serious bowel problems’ - (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect) - (S) ‘If symptoms persist consult your healthcare practitioner' (or words to that effect). When promoted or marketed as a laxative, the medicine requires the following warning statement on the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine label: - (LAX1) 'Drink plenty of water' (or words to that effect) When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]' - (LAX4) 'This product may have laxative effect' When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended' - (LAX1) 'Drink plenty of water' (or words to that effect) - (LAX2) 'Prolonged use may cause serious bowel problems' - (S) 'If symptoms persist consult your healthcare practitioner' (or words to that effect).

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1192	CASCARILLA OIL	A, H	The medicine must not contain more than 1mg of the equivalent dry herbal material per the maximum recommended daily dose.
1193	CASEIN	E	
1194	CASHEW NUT	E	
1195	CASSIA ALATA LEAF EXTRACT	E	Only for use as an excipient ingredient in sunscreens for dermal application and not to be intended for use in the eye. The extraction ratio of the Cassia alata can only be 1:3 in 62.5% glycerine:water. The concentration in the medicine must be no more than 0.0275%.
1196	CASSIA CINNAMON BARK DRY	A, H	When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% of coumarin.
1197	CASSIA CINNAMON BARK POWDER	A, H	When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% of coumarin.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1198	CASSIA FISTULA	A, H	Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Cassia fistula when the route of administration is oral. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (LAX2) ‘Prolonged use may cause serious bowel problems’ - (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect) - (S) ‘If symptoms persist consult your healthcare practitioner' (or words to that effect). When promoted or marketed as a laxative, the medicine requires the following warning statement on the

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			medicine label: - (LAX1) 'Drink plenty of water' (or words to that effect) When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]' - (LAX4) 'This product may have laxative effect' When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended' - (LAX1) 'Drink plenty of water' (or words to that effect) - (LAX2) 'Prolonged use may cause serious bowel problems' - (S) 'If symptoms persist consult your healthcare practitioner' (or words to that effect).

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1199	CASSIA OIL	A, E, H	The concentration of Cassia oil in the product must be no more than 2% unless the preparation is for dermal use as a rubefacient, in which case the concentration of cassia oil must be no more than 5%.
1200	CASSIE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1201	CASTANEA MOLLISSIMA	A, H	
1202	CASTANEA SATIVA	A, H	
1203	CASTOR OIL	A, E	
1204	CASTOREUM	H	Only permitted for use as an active homoeopathic ingredient.
1205	CASUARINA EQUISITIFOLIA	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1206	CATALPA BIGNONIOIDES	A, H	
1207	CATALPA OVATA	A, H	
1208	CATECHU	A, H	
1209	CATHARANTHUS ROSEUS	A, H	Vinblastine, vincamine, vincristine, vindesine, vinorelbine and yohimbine are mandatory components of Catharanthus roseus. The concentration of vinblastine, vincamine, vincristine, vindesine, vinorelbine and yohimbine in the medicine must be no more than 10mg/kg or 10 mg/L or 0.001%.
1210	CAULIFLOWER	E	
1211	CAULOPHYLLUM THALICTROIDES	A, E, H	
1212	CAUSTICUM	H	Only for use as an active homoeopathic ingredient.
1213	CEANOTHUS AMERICANUS	A, H	
1214	CEDAR LEAF OIL	A, E, H	
1215	CEDARWOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1216	CEDARWOOD OIL ATLAS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1217	CEDARWOOD OIL TERPENES	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1218	CEDARWOOD OIL VIRGINIA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
1219	CEDRENOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1220	CEDRENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1221	CEDROL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1222	CEDRUS ATLANTICA	A, E, H	
1223	CEDRUS DEODARA	A, H	
1224	CEDRUS LIBANI	H	Only for use as an active

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			homoeopathic ingredient.
1225	CEDRYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1226	CEDRYL METHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1227	CELERY LEAF	E, H	
1228	CELERY SEED DRY	A, E, H	
1229	CELERY SEED OIL	A, E, H	
1230	CELERY SEED POWDER	A, H	
1231	CELLACEFATE	E	
1232	CELLULASE	A	Must be derived from Trichoderma longibrachiatum only. If used as an undivided preparation, the allowed unit is Cellulase unit per gram or Thousand cellulase unit

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			per gram. If used as an divided preparation, the allowed unit is Thousand cellulase unit or cellulase unit.
1233	CELLULOSE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1234	CELOSIA ARGENTEA	A, H	
1235	CELOSIA ARGENTEA L. VAR. CRISTATA	A, H	
1236	CENTAUREA CYANUS	A, E, H	
1237	CENTAURIUM ERYTHRAEA	A, H	
1238	CENTELLA ASIATICA	A, E, H	
1239	CENTELLA ASIATICA MERISTEM CELL CULTURE	E	Only for use as an excipient ingredient in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.05%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1240	CENTIPEDA CUNNINGHAMII	A, E, H	
1241	CENTIPEDA MINIMA	A, H	
1242	CEPHALANOPSIS SEGETUM	A, H	
1243	CERAMIDE 1	E	Only for use in topical medicines for dermal application.
1244	CERAMIDE 2	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.05%.
1245	CERAMIDE 3	E	Only for use in topical medicines for dermal application.
1246	CERATONIA SILIQUA	A, E, H	
1247	CERATOSTIGMA WILLMOTTIANUM	A, H	
1248	CERESIN	E	Only for use in topical medicines for dermal application.
1249	CESTRUM LATIFOLIUM	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			use in the eye or on damaged skin. The plant part must be leaf and must be a water extract. The concentration must be no more than 0.5%.
1250	CETEARETH-12	E	Only for use in topical medicines for dermal application.
1251	CETEARETH-2	E	Only for use in topical medicines for dermal application.
1252	CETEARETH-20	E	Only for use in topical medicines for dermal application.
1253	CETEARETH-25	E	Only for use in topical medicines for dermal application.
1254	CETEARETH-30	E	Only for use in topical medicines for dermal application.
1255	CETEARETH-33	E	Only for use as an excipient ingredient for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			must be no more than 0.2%. Residual levels of 1,4-dioxane oxide (and related substances) are to be kept below the level of detection.
1256	CETEARYL GLUCOSIDE	E	Only for use in topical medicines for dermal application.
1257	CETEARYL ISONONANOATE	E	Only for use in topical medicines for dermal application.
1258	CETEARYL OCTANOATE	E	Only for use in topical medicines for dermal application.
1259	CETETH-10	E	Only for use in topical medicines for dermal application.
1260	CETETH-2	E	Only for use in topical medicines for dermal application.
1261	CETETH-24	E	Only for use in topical medicines for dermal application.
1262	CETETH-5	E	Only for use in topical medicines

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			for dermal application.
1263	CETOMACROGOL 1000	E	Only for use in topical medicines for dermal application.
1264	CETOMACROGOL 1000 PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
1265	CETOMACROGOL 500 PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
1266	CETOSTEARYL ALCOHOL	E	
1267	CETOSTEARYL ALCOHOL/COCO-GLUCOSIDE COMPLEX	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5.0 %

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1268	CETRARIA ISLANDICA	A, H	
1269	CETRIMONIUM BROMIDE	E	Only for use in topical medicines for dermal application.
1270	CETRIMONIUM CHLORIDE	E	Only for use in topical medicines for dermal application.
1271	CETYL ACETATE	E	Only for use in topical medicines for dermal application.
1272	CETYL ALCOHOL	E	Only for use in topical medicines for dermal application.
1273	CETYL DIMETHICONE COPOLYOL	E	Only for use in topical medicines for dermal application.
1274	CETYL DIMETICONE	E	Only for use in topical medicines for dermal application.
1275	CETYL DIMETICONE/BIS-VINYLDIMETICONE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1276	CETYL ESTERS WAX	E	Only for use in topical medicines for dermal application.
1277	CETYL HYDROXYETHYLCELLULOSE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
1278	CETYL LACTATE	E	Only for use in topical medicines for dermal application.
1279	CETYL OCTANOATE	E	Only for use in topical medicines for dermal application.
1280	CETYL PALMITATE	E	Only for use in topical medicines for dermal application.
1281	CETYL PHOSPHATE	E	Only for use in topical medicines for dermal application.
1282	CETYL-PG HYDROXYETHYL PALMITAMIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			use in the eye. The concentration in the medicine must be no more than 8%.
1283	CETYLPYRIDINIUM CHLORIDE	E	Only for use in topical medicines for dermal application. Medicines for topical use must include the name of any antimicrobial preservative in the goods.
1284	CHAENOMELES LAGENARIA	A, H	
1285	CHAENOMELES SPECIOSA	A, H	
1286	CHALK	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
1287	CHAMAECYPARIS LAWSONIANA	A, H	
1288	CHAMAELIRIUM LUTEUM	A, H	
1289	CHAMAEMELUM NOBILE	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1290	CHAMOMILE FLOWER DRY	A, E, H	
1291	CHAMOMILE OIL ENGLISH	A, E, H	
1292	CHAMOMILE OIL GERMAN	A, E, H	
1293	CHANGIUM SMYRNIOIDES	A, H	
1294	CHEIRANTHUS CHEIRI	A, H	
1295	CHELIDONIUM MAJUS	A, E, H	When for oral or sublingual use, the medicine requires the following warning statement on the medicine label: - (CELAND) 'WARNING: Greater Celandine may harm the liver in some people. Use only under the supervision of a healthcare professional'.
1296	CHELONE GLABRA	A, H	
1297	CHENOPODIUM ALBUM	A, H	
1298	CHENOPODIUM VULVARIA	A, H	
1299	CHERRY	E	
1300	CHERRY DISTILLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1301	CHESTNUT SWEET	E, H	
1302	CHILLI	E, H	
1303	CHIMAPHILA UMBELLATA	A, H	
1304	CHIONANTHUS VIRGINICA	A, H	
1305	CHLORELLA	E	Iodine is a mandatory component of Chlorella. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
1306	CHLORELLA PYRENOIDOSA	E	
1307	CHLORELLA VULGARIS	A, E	Iodine is a mandatory component of Chlorella vulgaris. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			recommended daily dose.
1308	CHLORHEXIDINE ACETATE	E	Only for use in topical medicines for dermal application.
1309	CHLORHEXIDINE GLUCONATE	E	Only for use in topical medicines for dermal application.
1310	CHLOROACETAMIDE	E	Only for use in topical medicines for dermal application.
1311	CHLOROBUTANOL HEMIHYDRATE	E	Only for use in topical preparations for localised effect. The concentration in the medicine must be no more than 0.5%. The medicine requires the following warning statement on the medicine label: - (CHLORB) 'Contains chlorbutol' (or words to that effect).
1312	CHLOROCRESOL	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 3%. The medicine requires the

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			following warning statement on the medicine label: - (CHLCRS) 'Contains chlorocresol [quantity]' (or words to that effect)
1313	CHLOROFORM	E	The residual solvent limit must be no more than 0.6 mg per recommended daily dose and the concentration in the medicine must be no more than 0.006%.
1314	CHLOROPHYLL	A, E	Only for use as a colour in oral and topical medicines.
1315	CHLOROPHYLL-COPPER COMPLEXES	E	Only for use as a colour in oral and topical medicines.
1316	CHLOROPHYLLIN-COPPER COMPLEX	E	Only for use as a colour in oral and topical medicines.
1317	CHLOROPHYLLIN-COPPER COMPLEX ALUMINIUM LAKE	E	Only for as a colour in oral and topical medicines.
1318	CHLOROXYLENOL	E	Only for use in topical medicines for dermal application.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1319	CHLORPHENESIN	E	Only for use in topical medicines for dermal application.
1320	CHOCOLATE BROWN HT	E	Permitted for use only as a colour for oral and topical use.
1321	CHOLESTEROL	E, H	Only for use as an active ingredient in homoeopathic medicines or an excipient ingredient in topical preparations.
1322	CHOLESTERYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application.
1323	CHOLESTERYL MACADAMIATE	E	Only for use in topical medicines for dermal application.
1324	CHOLESTERYL/BEHENYL/OCTYLDODECYL LAUROYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
1325	CHOLETH-24	E	Only for use in topical medicines for dermal application.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1326	CHOLINE BITARTRATE	A, E	
1327	CHOLINE DIHYDROGEN CITRATE	A	Only for use in oral medicines.
1328	CHONDRODENDRON TOMENTOSUM	A, H	The concentration of equivalent dry Chondrodendron tomentosum in the product must be no more than 10mg/Kg or 10mg/L or 0.001%.
1329	CHONDRUS CRISPUS	A, E, H	Iodine is a mandatory component of Chondrus crispus. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
1330	CHONDRUS DRY	A, E, H	Iodine is a mandatory component of Chondrus dry. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
1331	CHONDRUS EXTRACT	A, E, H	Iodine is a mandatory component of Chondrus extract. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
1332	CHROMIC CHLORIDE HEXAHYDRATE	A, H	When used as an active ingredient in a preparation for mineral supplementation, chromium is a mandatory component of chromic chloride hexahydrate. The amount of chromium in the active ingredient should be calculated based on the molecular weight of chromic chloride hexahydrate. The maximum recommended daily dose must provide 50 micrograms or less of chromium from organic sources (i.e. chromium picolinate,

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			chromium nicotinate and high chromium yeast).
1333	CHROMIUM NICOTINATE	A	Chromium is a mandatory component of chromium nicotinate. The maximum recommended daily dose must not provide more than 50 micrograms of chromium from organic sources. Chromium nicotinate is considered to be an organic form of chromium.
1334	CHROMIUM PICOLINATE	A	Chromium is a mandatory component of Chromium picolinate. The maximum recommended daily dose must not provide more than 50 micrograms of chromium from organic sources. Chromium picolinate is considered to be an organic form of chromium.
1335	CHRYSANTHEMUM BALSAMITA	A, H	
1336	CHRYSANTHEMUM INDICUM	A, H	
1337	CHRYSANTHEMUM LEUCANTHEMUM	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1338	CHRYSANTHEMUM MARSHALLII	A, H	
1339	CHRYSANTHEMUM SINENSE	A, H	
1340	CHRYSOPOGON ZIZANIOIDES	A, E, H	
1341	CHRYSOSPORIUM PRUINOSUM	A, H	
1342	CIBOTIUM BAROMETZ	A, H	
1343	CICHORIUM INTYBUS	A, E, H	
1344	CICUTA VIROSA	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
1345	CINCHONA BARK DRY	A, H	Quinidine and quinine are mandatory components of Cinchona bark dry. The medicine must contain no more than 50 micrograms of quinine and no more than 10 micrograms concentration of quinidine per g or mL.
1346	CINCHONA BARK POWDER	A, H	Quinidine and quinine are mandatory components of Cinchona bark powder. The medicine must contain no more than 50 micrograms of quinine and no more than 10 micrograms concentration of quinidine per g or

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			mL.
1347	CINCHONA OFFICINALIS	A, H	Quinidine and quinine are mandatory components of Cinchona officinalis. The medicine must contain no more than 50 micrograms of quinine and no more than 10 micrograms concentration of quinidine per g or mL.
1348	CINCHONA PUBESCENS	A, H	Quinidine and quinine are mandatory components of Cinchona pubescens. The medicine must contain no more than 50 micrograms of quinine and no more than 10 micrograms concentration of quinidine per g or mL.
1349	CINEOLE	E	In liquid preparations when the concentration of cineole in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
1350	CINNAMALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1351	CINNAMIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1352	CINNAMOMUM CAMPHORA	A, E, H	Camphor, cineole and safrole are mandatory components of Cinnamomum camphora. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%. In essential oil preparations or distillates, the nominal capacity of the container must be no more than 25 millilitres and the following warning statements must be included on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); - (NTAKEN) 'Not to be taken'; and - Do not apply to infants under 12 months of age except on the advice of a doctor or pharmacist. In essential oil preparations or

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			distillates, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container. In essential oil preparations or distillates, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container. In essential oil preparations or distillates, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container. In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect);

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			and - (NTAKEN) 'Not to be taken'. In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container. In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container. When for internal use then the concentration of safrole in a medicine must be no more than 0.1%. When for uses other than internal use, the concentration of safrole in a medicine must be no more than 1.0%. When used as an active ingredient, the maximum daily dose of the medicine must contain no more

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			than 0.001% of coumarin. If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25mL.
1353	CINNAMOMUM CASSIA	A, E	Cassia oil is a mandatory component of Cinnamomum cassia if the plant preparation is an essential oil, distillate, fixed oil or infused oil. The concentration of Cassia oil in the medicine must be no more than 2%. When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% of coumarin.
1354	CINNAMOMUM VERUM	A, E, H	When used as an active ingredient coumarin is a mandatory component of Cinnamomum verum and the maximum daily dose of the medicine must contain no more than 0.001% of coumarin. Cinnamon bark oil is a mandatory component of Cinnamomum verum when the plant part is bark and the plant preparation is essential oil, distillate, fixed oil or infused oil. The concentration of cinnamon

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			bark oil in the medicine must be no more than 2%. Cinnamon leaf oil is a mandatory component of Cinnamomum verum when the plant part is leaf. When the concentration of cinnamon leaf oil in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When the concentration of cinnamon leaf oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but no more than 25millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container. When the concentration of cinnamon leaf oil in the preparation

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the container must be fitted with a restricted flow insert.
1355	CINNAMON BARK OIL	A, E, H	The concentration of Cinnamon bark oil in the product must be no more than 2%. When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% Coumarin.
1356	CINNAMON DRY	A, H	Cinnamon bark oil is a mandatory component of Cinnamon dry. The concentration of cinnamon bark oil in the product must be no more than 2%. When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% of Coumarin.
1357	CINNAMON LEAF OIL	A, E, H	When the concentration of cinnamon leaf oil in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 mL. When the concentration of

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			cinnamon leaf oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL but no more than 25mL, the medicine must have a child resistant closure and restricted flow insert fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' When the concentration of cinnamon leaf oil in the preparation is more than 25% and the nominal capacity of the container is no more than 15 mL , the container must be fitted with a restricted flow insert and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% of Coumarin.
1358	CINNAMON POWDER	A, E, H	Cinnamon bark oil is a mandatory component of Cinnamon powder. The concentration of cinnamon

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			bark oil in the product must be no more than 2%. When used as an active ingredient, the maximum daily dose of the medicine must contain no more than 0.001% Coumarin.
1359	CINNAMYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1360	CINNAMYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1361	CINNAMYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1362	CINNAMYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1363	CINNAMYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1364	CINNAMYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1365	CINNAMYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
1366	CINNAMYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1367	CINOXATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 6%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1368	CIS-2-METHYL-4-PROPYL-1,3-OXATHIANE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1369	CIS-3-HEXEN-1-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance. Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1370	CIS-3-HEXENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1371	CIS-3-HEXENYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1372	CIS-3-HEXENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1373	CIS-3-HEXENYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1374	CIS-3-HEXENYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1375	CIS-3-HEXENYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%.
1376	CIS-3-HEXENYL HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1377	CIS-3-HEXENYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1378	CIS-3-HEXENYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1379	CIS-3-HEXENYL LACTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1380	CIS-3-HEXENYL METHYL CARBONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1381	CIS-3-HEXENYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1382	CIS-3-HEXENYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
1383	CIS-4-HEPTENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1384	CIS-6-NONEN-1-AL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1385	CIS-6-NONENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1386	CIS-BETA-OCIMENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1387	CIS-HEXAHYDROCUMINYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1388	CIS-JASMONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			medicine must be no more 1%.
1389	CISTANCHE DESERTICOLA	A, H	
1390	CISTANCHE SALSA	A, H	
1391	CISTUS LADANIFERUS	A, E, H	
1392	CITRAL	E	
1393	CITRAL DIETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1394	CITRAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1395	CITRIC ACID	A, E	Where intended for topical use, sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When used as an active ingredient

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			in preparations for topical use, the medicine requires the following warning statements on the medicine label: - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect) - (SUNPRO) 'Wear protective clothing, hats and eyewear when exposed to the sun.' (or words to that effect) - (IRRIT) 'If irritation develops, discontinue use.' - (SKTEST) 'If you have sensitive skin, test this product on a small area of skin before applying it to a large area.' - (CHILD3) 'Use in children under 12 years is not recommended'
1396	CITRIC ACID DIHYDRATE	A, E	Where intended for topical use, sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When used as an active ingredient in preparations for topical use, the medicine requires the following warning statements on the medicine label:

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			- (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect) - (SUNPRO) 'Wear protective clothing, hats and eyewear when exposed to the sun.' (or words to that effect) - (IRRIT) 'If irritation develops, discontinue use.' - (SKTEST) 'If you have sensitive skin, test this product on a small area of skin before applying it to a large area.' - (CHILD3) 'Use in children under 12 years is not recommended'
1397	CITRIC ACID MONOHYDRATE	A, E	Where intended for topical use, sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When used as an active ingredient in preparations for topical use, the medicine requires the following warning statements on the medicine label: - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect) - (SUNPRO) 'Wear protective

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			clothing, hats and eyewear when exposed to the sun.' (or words to that effect) - (IRRIT) 'If irritation develops, discontinue use.' - (SKTEST) 'If you have sensitive skin, test this product on a small area of skin before applying it to a large area.' - (CHILD3) 'Use in children under 12 years is not recommended.'
1398	CITRIC AND FATTY ACID ESTERS OF GLYCEROL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1399	CITROL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1400	CITRON	E	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1401	CITRONELLA OIL	A, E, H	Medicines for topical use containing citronella oil require the following warning statement on the medicine label: - (CITRON) 'Contains citronella oil'.
1402	CITRONELLA TERPENES	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1403	CITRONELLAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1404	CITRONELLIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1405	CITRONELLOL	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
1406	CITRONELLYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1407	CITRONELLYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1408	CITRONELLYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1409	CITRONELLYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1410	CITRONELLYL NITRILE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1411	CITRONELLYL OXYACETALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1412	CITRONELLYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1413	CITRONELLYL TIGLATE	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1414	CITRONNOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1415	CITRULLUS COLOCYNTHIS	H	Only for use as an active homoeopathic ingredient. When for oral use, the concentration of Citrullus colocynthis must be more than 4X (i.e. 1X 2X 3X).
1416	CITRULLUS VULGARIS	A, H	
1417	CITRUS AURANTIFOLIA	A, E, H	When the plant preparation is oil or distillate, the warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			b) in preparations containing 0.5% or less of citrus aurantifolia oil or distillate; or c) for use in soaps or bath or shower gels that are washed off the skin.
1418	CITRUS AURANTIUM	A, E, H	Oxedrine is a mandatory component of Citrus aurantium when intended for internal use. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg. When the plant preparation is oil or distillate, the warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 1.4% or less of citrus aurantium oil or distillate; or c) for use in soaps or bath or shower gels that are washed off the skin.
1419	CITRUS BIOFLAVONOIDS	A, E, H	

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	EXTRACT		
1420	CITRUS CHACHIENSIS	A, H	
1421	CITRUS EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1422	CITRUS FIBRE	E	
1423	CITRUS LIMETTA	A, H	When the plant preparation is oil or distillate, the warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 0.5% or less of citrus limetta oil or distillate; or c) for use in soaps or bath or shower gels that are washed off the skin.
1424	CITRUS LIMON	A, E, H	Oxedrine is a mandatory component of Citrus limon when intended for internal use.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams. When the plant preparation is oil or distillate, the warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 0.05% or less of citrus limon oil or distillate; or c) for use in soaps or bath or shower gels that are washed off the skin.
1425	CITRUS MAXIMA	A, H	
1426	CITRUS MEDICA	A, E, H	When the plant preparation is oil or distillate, the warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 0.05% or less of citrus medica oil or

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			distillate; or c) for use in soaps or bath or shower gels that are washed off the skin.
1427	CITRUS OIL DISTILLED	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1428	CITRUS RETICULATA	A, E, H	Oxedrine is a mandatory component of Citrus reticulata when intended for internal use. The quantity of Oxedrine in the recommended daily dose must be no more than 30 mg.
1429	CITRUS SINENSIS	A, E, H	Oxedrine is a mandatory component of Citrus sinensis when intended for internal use. The quantity of Oxedrine in the recommended daily dose must be no more than 30 mg.
1430	CITRUS SINENSIS PEEL	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
	MOLASSES EXTRACT		ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1431	CITRUS UNSHIU	A, E, H	Oxedrine is a mandatory component of Citrus unshiu when intended for internal use. The quantity of Oxedrine in the recommended daily dose must be no more than 30 mg.
1432	CITRUS X PARADISI	A, E, H	
1433	CITRUS X WILSONII	A, H	
1434	CIVET	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1435	CIVET ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1436	CIVET SYNTHETIC	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1437	CIVETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1438	CLARY OIL	A, E, H	
1439	CLEMATIS ARMANDII	A, H	
1440	CLEMATIS CHINENSIS	A, E, H	
1441	CLEMATIS RECTA	A, H	
1442	CLEMATIS VITALBA	A, H	
1443	CLERODENDRUM TRICHOTOMUM	A, H	
1444	CLINOPODION POLYCEPHALUM	A, H	
1445	CLINOPODIUM NEPETA SUBSP.	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
	GLANDULOSUM		
1446	CLIVER HERB DRY	A, H	
1447	CLIVER HERB POWDER	A, H	
1448	CLOVE BUD OIL	A, E, H	When the concentration of Clove Bud Oil in the preparation is more than 25%, the nominal capacity of the container must be no more than 25 mL. When the concentration of Clove Bud Oil in the preparation is more than 25% and the nominal capacity of the container is more 15 mL but no more than 25mL, a child resistant closure and restricted flow insert must be fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' When the concentration of clove bud oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL , a restricted flow insert must be fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			children' (or words to that effect) - (NTAKEN) 'Not to be taken'
1449	CLOVE DRY	A, E, H	
1450	CLOVE LEAF OIL	A, E, H	When the concentration of Clove Leaf Oil in the preparation is more than 25%, the nominal capacity of the container must be no more than 25 mL. When the concentration of Clove Leaf Oil in the preparation is more than 25% and the nominal capacity of the container is more 15 mL but no more than 25mL, a child resistant closure and restricted flow insert must be fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' When the concentration of clove leaf oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			children' (or words to that effect) - (NTAKEN) 'Not to be taken'
1451	CLOVE OIL TERPENES	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1452	CLOVE POWDER	A, E, H	
1453	CLOVE STEM OIL	A, E, H	When the concentration of Clove Stem Oil in the preparation is more than 25%, the nominal capacity of the container must be no more than 25 mL. When the concentration of Clove Stem Oil in the preparation is more than 25% and the nominal capacity of the container is more 15 mL but no more than 25mL, a child resistant closure and restricted flow insert must be fitted on the container requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken'

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			When the concentration of Clove Stem oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL , a restricted flow insert must be fitted on the container and requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken'
1454	CLUPEA HARENGUS LIPID EXTRACT	A	Only for use in oral medicines. The maximum recommended daily dose must not provide more than 2750 mg EPA, DHA and DPA combined, when used alone or in combination with other sources of omega-3 fatty acids.
1455	CNICUS BENEDICTUS	A, H	
1456	CNICUS JAPONICUS	A, H	
1457	CNIDIUM MONNIERI	A, H	
1458	CNIDIUM OFFICINALE	A, H	
1459	COBALTOUS NITRATE HEXAHYDRATE	H	Only for use as an active homoeopathic ingredient.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1460	COCAMIDE DEA	E	Only for use in topical medicines for dermal application.
1461	COCAMIDE MEA	E	Only for use in topical medicines for dermal application.
1462	COCAMIDOPROPYL BETAINAMIDE MEA CHLORIDE	E	Only for use in topical medicines for dermal application and not to be included in topical products intended for use in the eye. The concentration in the medicine must be no more than 1%.
1463	COCAMIDOPROPYL BETAINE	E	Only for topical, mucous membrane (buccal mucosa) and dental use and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be: a) no more than 1% in leave on medicines b) no more than 15% in wash on /wash off medicines c) 1.2% for buccal mucosa and dental medicines. Levels of impurities 3-dimethylaminopropylamine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			(DMAPA) and amidoamine (dimethylaminopropylcocoamide; AA) must be controlled to below the level of detection.
1464	COCCOLOBIA UVIFERA	A, H	
1465	COCCULUS ORBICULATUS	A, H	
1466	COCHINEAL	E, H	Only for use as an active homoeopathic ingredient or for excipient use only as a colour in oral and topical medicines.
1467	COCHLEARIA OFFICINALIS	A, H	
1468	COCILLANA DRY	A, H	
1469	COCILLANA POWDER	A, H	
1470	COCO-BETAINE	E	Only for use in topical medicines for dermal application.
1471	COCO-CAPRYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration is to be no more than 12.5% in the medicine.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1472	COCO-GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.025%
1473	COCO-OCTANOATE/DECANOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
1474	COCOA EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1475	COCOA POWDER	A, E, H	
1476	COCOGLYCERIDES	E	
1477	COCONUT	E	
1478	COCONUT ACID	E	Only for use in topical medicines for dermal application.
1479	COCONUT OIL	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1480	COCOS NUCIFERA	A, E, H	
1481	COD-LIVER OIL	A, E	Vitamin A and colecalciferol are mandatory components of Cod-liver oil. When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%. When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents. When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.' NOTE: Position this warning at the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			beginning of the directions for use. - (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.' When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of vitamin D.
1482	CODONOPSIS LANCEOLATA	A, H	
1483	CODONOPSIS PILOSULA	A, H	
1484	CODONOPSIS TANGSHEN	A, H	
1485	COFFEA ARABICA	A, E, H	Caffeine is a mandatory component of Coffea arabica. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine requires the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1486	COFFEA CANEPHORA	A, E, H	Caffeine is a mandatory component of Coffea canephora. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1487	COFFEE	E, H	Caffeine is a mandatory component

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			of coffee. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1488	COFFEE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1489	COFFEE SOLID EXTRACT	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1490	COGNAC OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1491	COGNAC OIL GREEN	A, E, H	
1492	COGNAC OIL WHITE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1493	COIX LACHRYMA-JOBI	A, H	
1494	COLA ACUMINATA	A, E, H	Caffeine is a mandatory component of Cola acuminata. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of:

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the warning statement: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the warning statement: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1495	COLA COTYLEDON DRY	A, H	Caffeine is a mandatory component of Cola cotyledon dry. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the warning statement: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the warning statement: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			or per gram of product]'.
1496	COLA COTYLEDON POWDER	A, H	Caffeine is a mandatory component of Cola cotyledon powder. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine requires the warning statement: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the warning statement: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1497	COLA NITIDA	A, E, H	Caffeine is a mandatory component of Cola nitida. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of: a) more than 1 mg but no more than 10 mg of caffeine the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			requires the warning statement: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' b) more than 10 mg of caffeine the medicine requires the warning statement: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
1498	COLCHICUM AUTUMNALE	H	Only for use as an active homoeopathic ingredient.
1499	COLECALCIFEROL	A, E	When for internal use, the maximum recommended daily dose must not be more than 25 micrograms of Vitamin D.
1500	COLLAGEN	E	
1501	COLLINSONIA CANADENSIS	A, H	
1502	COLLOIDAL ANHYDROUS SILICA	A, E, H	Only for use when the route of administration is other than inhalation.
1503	COLOPHONY	A, E, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1504	COMMIPHORA HABESSINICA	A, H	
1505	COMMIPHORA KATAF	A, H	
1506	COMMIPHORA MYRRHA	A, E, H	
1507	COMMON INDIAN COBRA	H	Only for use as an active homoeopathic ingredient.
1508	CONCENTRATED FISH OMEGA-3 TRIGLYCERIDES	A	Only for oral use.
1509	CONCENTRATED SQUID OMEGA-3 TRIGLYCERIDES	A	Only for oral use. 'Concentrated squid omega-3-triglycerides' must be obtained from species of the order Teuthida of the class Cephalopoda AND be in combination with other ingredients in the preparation AND be presented in a therapeutic dosage form for therapeutic use. The medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
1510	CONIFER GREEN NEEDLE COMPLEX	A	Only for topical and oral use. Must be made by petroleum ether extraction of needles of the conifer species Pinus sylvestris (Scotch Pine) and Picea abies (Norwegian

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			Spruce).
1511	CONIFER PHYTOSTEROL COMPLEX	A	
1512	CONIOSELIUM UNIVITTATUM	A, H	
1513	CONIUM MACULATUM	H	Only for use as an active homoeopathic ingredient. The concentration must be no more than exceed 12X homoeopathic dilution.
1514	CONVALLARIA MAJALIS	A, H	The concentration of equivalent dry Convallaria majalis in the product must be no more than 10mg/Kg or 10mg/L or 0.001%.
1515	CONYZA CANADENSIS	A, H	
1516	COPAIBA OIL	A, E, H	
1517	COPAIFERA LANGSDORFFII	A, E, H	
1518	COPERNICIA CERIFERA	A, E, H	
1519	COPOVIDONE	E	
1520	COPPER	H	Only for use as an active homoeopathic ingredient. When for internal use the maximum daily dose must not contain more

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%.
1521	COPPER (II) ASPARTATE	A, H	Copper is a mandatory component of copper (II) aspartate. The percentage of copper from copper (II) aspartate should be calculated based on the molecular weight of copper (II) aspartate. The concentration of copper compounds in products must be no more than 5%. The maximum daily dose must not contain more than 5mg of copper.
1522	COPPER (II) GLYCINATE	A, H	Copper is a mandatory component of copper (II) glycinate. The percentage of copper from copper (II) glycinate should be calculated based on the molecular weight of Copper (II) glycinate. The concentration of copper compounds in products must be no more than 5%. The maximum daily dose must not

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			contain more than 5mg of copper.
1523	COPPER (II) LYSINATE	A, H	Copper is a mandatory component of copper (II) lysinate. The percentage of copper from copper (II) lysinate should be calculated based on the molecular weight of Copper (II) lysinate. The concentration of copper compounds in products must be no more than 5%. The maximum daily dose must not contain more than 5mg of copper.
1524	COPPER ACETYL TYROSINATE METHYLSILANOL	E	Only for use in topical medicines for dermal application.
1525	COPPER CHLOROPHYLL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1526	COPPER CHLOROPHYLLIN	E	Only for use as a colour in oral and topical medicines.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1527	COPPER GLUCONATE	A, E	Copper is a mandatory component of copper gluconate. The percentage of copper from copper gluconate should be calculated based on the molecular weight of copper gluconate. When for internal use the maximum daily dose must not contain more than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%.
1528	COPPER TRIPEPTIDE-1	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 3%.
1529	COPTIS CHINENSIS	A, H	
1530	COPTIS JAPONICA	A, H	
1531	CORALLINA OFFICINALIS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine is to be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1532	CORDYCEPS SINENSIS	A, E, H	Must not contain material of animal origin such as insect larvae.
1533	CORIANDER DRY	A, H	
1534	CORIANDER OIL	A, E, H	
1535	CORIANDER POWDER	A, H	
1536	CORIANDRUM SATIVUM	A, E, H	
1537	CORN GLYCERIDES	E	
1538	CORN SILK DRY	A, H	
1539	CORN SILK POWDER	A, H	
1540	CORN SYRUP	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1541	CORN SYRUP SOLIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1542	CORNUS FLORIDA	A, H	
1543	CORNUS OFFICINALIS	A, H	
1544	CORTISONE ACETATE	H	Only available as an active homoeopathic ingredient.
1545	CORYDALIS AMBIGUA	A, E, H	
1546	CORYDALIS BUNGEANA	A, H	
1547	CORYDALIS CAVA	A, H	
1548	CORYDALIS FABACEA	A, H	
1549	CORYDALIS FORMOSA	A, H	
1550	CORYDALIS TURTSCHANINOVII	A, H	
1551	CORYLUS AMERICANA	A, H	
1552	CORYLUS AVELLANA	A, H	
1553	CORYMBIA CITRIODORA	A, E, H	Cineole is a mandatory component of Corymbia citriodora. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
1554	CORYMBIA FICIFOLIA	A, H	Cineole is a mandatory component of Corymbia ficifolia. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label:

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
1555	COSMOS BIPINNATUS	A, H	
1556	COSTUS ROOT OIL	A, H	
1557	COSTUS SPICATUS	A, H	
1558	COTTONSEED OIL	A, E, H	
1559	COUCH GRASS RHIZOME DRY	A, H	
1560	COUCH GRASS RHIZOME POWDER	A, H	
1561	COUMARIN	H	Only for use as an active homoeopathic ingredient. The concentration in the medicine must be no more than 0.001%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1562	CRANBERRY	E	
1563	CRATAEGUS CUNEATA	A, E, H	
1564	CRATAEGUS LAEVIGATA	A, E, H	
1565	CRATAEGUS MONOGYNA	A, E, H	
1566	CRATAEGUS PINNATIFIDA	A, E, H	
1567	CRATEVA MAGNA	A, E, H	
1568	CREATINE	A, E	
1569	CREATINE MONOHYDRATE	A, E	
1570	CREATINE PHOSPHATE	A, E	
1571	CREATININE	E	Only for use in topical medicines for dermal application and not for use in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.2%.
1572	CREOSOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
1573	CREOSOTE	H	Only for use as an active homoeopathic ingredient.
1574	CRESOL	E	Only for use as a preservative in topical medicines. The concentration of phenols (including cresols and xylenols and any other homologue of phenol) boiling below 220 degrees centigrade must be no more than 3%. The medicine requires the following warning statement on the medicine label: - (CRESOL) 'Contains cresol' (or words to that effect)
1575	CRESYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1576	CRITHMUM MARITIMUM	E	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
	WHOLE PLANT EXTRACT		included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.00341%.
1577	CROCUS SATIVUS	A, H	
1578	CROSCARMELLOSE SODIUM	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1579	CROSPOVIDONE	E	
1580	CROTON CASCARILLA	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
1581	CROTON ELUTERIA	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1582	CRYPTOMERIA JAPONICA	A, H	
1583	CUBEB OIL	A, H	
1584	CUBEBENE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1585	CUCUMBER	E	
1586	CUCUMIS MELO	A, H	
1587	CUCUMIS SATIVUS	A, E, H	
1588	CUCURBITA MAXIMA	A, E, H	
1589	CUCURBITA MOSCHATA	A, H	
1590	CUCURBITA PEPO	A, E, H	
1591	CULLEN CORYLIFOLIUM	A, H	
1592	CUMIC ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1593	CUMIN OIL	A, E, H	
1594	CUMINALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1595	CUMINUM CYMINUM	A, H	
1596	CUMINYL NITRILE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1597	CUPRESSUS ARIZONICA	A, H	
1598	CUPRESSUS FUNEBRIS	A, E, H	
1599	CUPRESSUS MACROCARPA	A, H	
1600	CUPRESSUS SEMPERVIRENS	A, E, H	
1601	CUPRIC ACETATE MONOHYDRATE	H	Only for use as an active homoeopathic ingredient.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
1602	CUPRIC ARSENITE	H	Only for use as an active homoeopathic ingredient.
1603	CUPRIC CITRATE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric citrate. The percentage of copper from cupric citrate should be calculated based on the molecular weight of cupric citrate. The medicine must not contain more than 750 micrograms of copper from cupric citrate per the recommended daily dose or the medicine must not contain more than 1.86 milligrams of cupric citrate per the recommended daily dose.
1604	CUPRIC CITRATE HEMIPENTAHYDRATE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric citrate hemipentahydrate. The percentage of copper from cupric citrate hemipenthydrate should be calculated based on the molecular weight of cupric citrate hemipenthydrate. The medicine must not contain more than 750 micrograms of

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			copper from cupric citrate hemipentahydrate per the recommended daily dose OR the medicine must not contain more than 2.13 milligrams of cupric citrate hemipentahydrate per the recommended daily dose.
1605	CUPRIC OXIDE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric oxide. The percentage of copper from cupric oxide should be calculated based on the molecular weight of cupric oxide. When for internal use the maximum daily dose must not contain more than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%.
1606	CUPRIC SULFATE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric sulfate. The percentage of copper from cupric sulfate should be calculated based on the molecular weight of cupric sulfate. When for internal use the maximum

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			daily dose must not contain more than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%.
1607	CUPRIC SULFATE MONOHYDRATE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric sulfate monohydrate. The percentage of copper from cupric sulfate monohydrate should be calculated based on the molecular weight of cupric sulfate monohydrate. When for internal use the maximum daily dose must not contain more than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%. When used topically, cupric sulfate is a mandatory component of cupric sulfate monohydrate.
1608	CUPRIC SULFATE PENTAHYDRATE	A, E, H	When for oral or sublingual use, copper is a mandatory component of cupric sulfate pentahydrate. The percentage of copper from

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			cupric sulfate pentahydrate should be calculated based on the molecular weight of cupric sulfate pentahydrate. When for internal use the maximum daily dose must not contain more than 5 mg of copper. When for other than internal use, the concentration of copper compounds must be no more than 5%. When used topically cupric sulfate is a mandatory component of cupric sulfate pentahydrate. The percentage of cupric sulfate from cupric sulfate pentahydrate should be calculated based on the molecular weight of cupric sulfate pentahydrate.
1609	CURCULIGO ORCHIOIDES	A, H	
1610	CURCUMA AROMATICA	A, H	
1611	CURCUMA LONGA	A, E, H	
1612	CURCUMA XANTHORRHIZA	A, H	
1613	CURCUMA ZEDOARIA	A, H	
1614	CURCUMIN	A, E, H	When for excipient use, only permitted for use as a colour in topical and oral medicines.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1615	CUSCUTA EPITHYMUM	A, H	
1616	CUSCUTA EUROPAEA	A, H	
1617	CUSCUTA HYGROPHILAE	A, H	
1618	CUSCUTA RACEMOSA	A, H	
1619	CUSPARIA FEBRIFUGA	A, H	
1620	CYAMOPSIS TETRAGONOLOBA	A, E, H	
1621	CYANOCOBALAMIN	A, E, H	
1622	CYANOMETHYLPHENYL MENTHANE CARBOXAMIDE	E	For dental use only in proprietary ingredients. Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
1623	CYATHULA OFFICINALIS	A, H	
1624	CYCLAMEN ALDEHYDE	E	Only for use as an excipient ingredient in topical medicines.
1625	CYCLAMEN PURPURASCENS	A, H	
1626	CYCLOHEXADECENONE-8	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1627	CYCLOHEXANE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1628	CYCLOHEXANE, 1-ETHENYL-1-METHYL-2-(1-METHYLETHENYL)-4-(1-METHYLETHYL)-, DIDEHYDRO DERIV.	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1629	CYCLOHEXANEETHANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1630	CYCLOHEXYL ACETATE	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1631	CYCLOHEXYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
1632	CYCLOHEXYL PHENETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1633	CYCLOHEXYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1634	CYCLOHEXYLETHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
1635	CYCLOMETHICONE	E	Only for use as an excipient ingredient in topical medicines.
1636	CYCLOPENTADECANONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1637	CYDONIA OBLONGA	A, H	
1638	CYMBOPOGON FLEXUOSUS	A, E, H	The concentration or Aldehydes calculated as citral in the medicine must be no more than 5% for topical use.
1639	CYMBOPOGON MARTINI	A, H	The concentration or Aldehydes calculated as citral in the medicine must be no more than 5% for topical use.
1640	CYMBOPOGON NARDUS	A, H	The concentration or Aldehydes calculated as citral in the medicine must be no more than 5% for topical use.
1641	CYMBOPOGON SCHOENANTHUS	A, E, H	The concentration or Aldehydes calculated as citral in the medicine must be no more than 5% for topical use.
1642	CYNANCHUM ATRATUM	A, H	
1643	CYNANCHUM STAUNTONII	A, E, H	
1644	CYNARA SCOLYMUS	A, E, H	
1645	CYNODON DACTYLON	A, E, H	
1646	CYNOMORIUM COCCINEUM	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
	SUBSP. SONGARICUM		
1647	CYPERUS LONGUS	A, H	
1648	CYPERUS ROTUNDUS	A, H	
1649	CYPRESS OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1650	CYPRIPEDIUM PARVIFLORUM VAR. PUBESCENS	A, H	
1651	CYSTEINE	A	
1652	CYSTEINE HYDROCHLORIDE	A	
1653	CYSTEINE HYDROCHLORIDE MONOHYDRATE	A, E	When used as an excipient, permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1654	CYSTINE	A	
1655	CYTISUS SCOPARIUS	A, H	Sparteine is a mandatory component of Cytisus scoparius. The concentration of Sparteine in

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			the medicine must be no more than 0.001%.
1656	D-ALPHA-TOCOPHEROL	A, E	
1657	D-ALPHA-TOCOPHERYL ACETATE	A, E, H	
1658	D-ALPHA-TOCOPHERYL ACID SUCCINATE	A, E	
1659	D-ALPHA-TOCOPHERYL PHOSPHATES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 3%.
1660	D-BORNEOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1661	D-CARVONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1662	D-FENCHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1663	D-LIMONENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1664	D-PULEGONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%. The concentration of d-pulegone in the medicine must not be more than 4%.
1665	D-RIBOSE-L-CYSTEINE	A	Only for use in oral medicines. Cysteine is a mandatory component of D-Ribose-L-Cysteine. The medicine must provide no more than 450 mg of cysteine per maximum recommended daily dose.
1666	DACTYLIS GLOMERATA	A, H	
1667	DACTYLORHIZA INCARNATA SUBSP. INCARNATA	A, H	
1668	DAEMONOROPS DRACO	A, E, H	
1669	DAHLIA PINNATA	A, H	
1670	DALBERGIA ODORIFERA	A, H	
1671	DAMIANA LEAF POWDER	A	
1672	DANDELION LEAF DRY	A, H	
1673	DANDELION LEAF POWDER	A, H	
1674	DANDELION ROOT DRY	A, H	
1675	DANDELION ROOT POWDER	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1676	DAPHNE GENKWA	A, H	
1677	DAPHNE MEZEREUM	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
1678	DATE	E	
1679	DATURA STRAMONIUM	A, H	Only for use in oral medicines. Alkaloids calculated as hyoscyamine is a mandatory component of Datura stramonium. The concentration of alkaloids calculated as hyoscyamine from all ingredients in the product must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%.
1680	DAUCUS CAROTA	A, E, H	
1681	DAVANA OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1682	DEA-OLETH-3 PHOSPHATE	E	Only for use in topical medicines for dermal application and not be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1%. The medicine requires the following warning statements on the medicine label: - (EYE) 'Avoid contact with eyes' - (EYE2) 'May be irritant to the eyes' (or words to that effect).
1683	DECAHYDRO-2,2,6,6,7,8,8-HEPTAMETHYL-2H-INDENO(4,5-B) FURAN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1684	DECAHYDRO-BETA-NAPHTHYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1685	DECAHYDRO-BETA-NAPHTHYLFORMATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1686	DECAHYDROSPIRO(FURAN-2(3H),5'-(4,7)METHANO(5H)INDENE)	E	Permitted for use only in combination with other permitted ingredients as a fragrance. The total fragrance concentration in a medicine must be no more than 1%.
1687	DECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1688	DECANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1689	DECANAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1690	DECARBOXY CARNOISINE DIHYDROCHLORIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.05.
1691	DECENAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1692	DECYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1693	DECYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1694	DECYL GLUCOSIDE	E	Only for use in topical medicines for dermal application.
1695	DECYL OLEATE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1696	DECYLENE GLYCOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.5%.
1697	DEER ANTLER CARTILAGE	H	Only for use as an active homoeopathic ingredient.
1698	DEER VELVET ANTLER POWDER	A	Medicines that contain 'deer velvet antler powder' as the therapeutically active ingredient are subject to the following conditions: a) the medicines are for oral use only; b) the antlers (including the velvet) are sourced only from red deer (Cervus elaphus), elk/wapiti (Cervus canadensis), or a crossbreed of these species; c) the deer are sourced only from farmed stock bred and raised in New Zealand; d) the deer are sourced only from herds farmed for food in accordance with the Animal Products Act 1999 (New Zealand) and the regulations made under that Act, as in force or existing from

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			time to time; e) the antlers are removed from the deer only according to the Animal Welfare Act 1999 (New Zealand) and the regulations made under that Act, as in force or existing from time to time.
1699	DEER VELVET ANTLER SLICE	A	Medicines that contain 'deer velvet antler slice' as the therapeutically active ingredient are subject to the following conditions: a) the medicines are for oral use only; b) the antlers (including the velvet) are sourced only from red deer (Cervus elaphus), elk/wapiti (Cervus canadensis), or a crossbreed of these species; c) the deer are sourced only from farmed stock bred and raised in New Zealand; d) the deer are sourced only from herds farmed for food in accordance with the Animal Products Act 1999 (New Zealand) and the regulations made under that Act, as in force or existing from time to time; e) the antlers are removed from the deer only according to the Animal

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			Welfare Act 1999 (New Zealand) and the regulations made under that Act, as in force or existing from time to time.
1700	DEERTONGUE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1701	DEHYDROACETIC ACID	E	Only for use in topical medicines for dermal application. The medicine requires the following warning statement on the medicine label: - (DACACD) 'Contains dehydroacetic acid [quantity]' (or words to that effect).
1702	DEHYDROMENTHOFUROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
1703	DEHYDROXANTHAN GUM	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.
1704	DELPHINIUM STAPHISAGRIA	A, H	The concentration of the equivalent dry Delphinium staphisagria in the medicine must be no more than 0.2%.
1705	DELTA-DAMASCONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1706	DELTA-DECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1707	DELTA-DODECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1708	DELTA-NONALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1709	DELTA-OCTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1710	DELTA-TETRADECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1711	DELTA-TOCOPHEROL	E	
1712	DELTA-UNDECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1713	DEMINERALISED FISH PROTEOGLYCAN EXTRACT	A	
1714	DENATONIUM BENZOATE	E	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1715	DENDROBIUM NOBILE	A, H	
1716	DESCURAINIA SOPHIA	A, H	
1717	DESMODIUM STYRACIFOLIUM	A, H	
1718	DESMODIUM TRIQUETUM	A, H	
1719	DEVIL'S CLAW TUBER DRY	A, H	
1720	DEVIL'S CLAW TUBER POWDER	A, H	
1721	DEXPANTHENOL	A, E	
1722	DEXTRAN 20	E	Only for use in topical medicines for dermal application and not be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.3%.
1723	DEXTRAN 40	A, E	
1724	DEXTRATES	E	
1725	DEXTRIN	E	
1726	DEXTRIN PALMITATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1727	DHA/EPA RICH SCHIZOCHYTRIUM ALGAL OIL	A	Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are mandatory components of DHA/EPA rich schizochytrium algal oil. Only for use in oral medicines when in combination with other active or excipient ingredients. The ratio of DHA to EPA must be 2:1.
1728	DI-C12-13 ALKYL MALATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
1729	DI-C12-15 ALKYL FUMARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
1730	DI-N-PROPYL ISOCINCHOMERONATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			must be no more than 25%.
1731	DI-PPG-3 MYRISTYL ETHER ADIPATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 15%.
1732	DIACETIN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1733	DIACETYL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
1734	DIACETYL TARTARIC ACID ESTERS OF MONO- AND DIGLYCERIDES	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1735	DIACETYLATED MONOGLYCERIDES	E	Permitted for use only in combination with other permitted ingredients as a coating solution.
1736	DIAMMONIUM LAURYL SULFOSUCCINATE	E	Only for use as an excipient ingredient in topical medicines.
1737	DIANTHUS SUPERBUS	A, H	
1738	DIAZOLIDINYL UREA	E	Only for use in topical medicines for dermal application. The medicine requires the following warning statement on the medicine label: - (DUREA) 'Contains diazolidinyl urea' (or words to that effect).
1739	DIBASIC MAGNESIUM CITRATE	A	Only for use in oral medicines.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	TETRAHYDRATE		
1740	DIBASIC MAGNESIUM PHOSPHATE TRIHYDRATE	A, E, H	Magnesium is a mandatory component of dibasic magnesium phosphate trihydrate. The percentage of magnesium from dibasic magnesium phosphate trihydrate should be calculated based on the molecular weight of dibasic magnesium phosphate trihydrate.
1741	DIBASIC POTASSIUM PHOSPHATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of dibasic potassium phosphate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
1742	DIBASIC POTASSIUM PHOSPHATE TRIHYDRATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of dibasic potassium phosphate trihydrate. When used in a solid preparation,

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
1743	DIBASIC SODIUM PHOSPHATE	A, E, H	When used as an active ingredient and the preparation is intended as a mineral supplementation, sodium is a mandatory component of dibasic sodium phosphate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1744	DIBASIC SODIUM PHOSPHATE	A, E, H	When used as an active ingredient and the preparation is intended as a

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	DIHYDRATE		mineral supplementation, sodium is a mandatory component of dibasic sodium phosphate dihydrate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1745	DIBASIC SODIUM PHOSPHATE DODECAHYDRATE	A, E, H	When used as an active ingredient and the preparation is intended as a mineral supplementation, sodium is a mandatory component of dibasic sodium phosphate dodecahydrate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			preparation must not exceed 11.5. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1746	DIBASIC SODIUM PHOSPHATE HEPTAHYDRATE	A, E, H	When used as an active ingredient and the preparation is intended as a mineral supplementation, sodium is a mandatory component of dibasic sodium phosphate heptahydrate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1747	DIBASIC SODIUM PHOSPHATE MONOHYDRATE	A, E, H	When used as an active ingredient and the preparation is intended as a mineral supplementation, sodium is a mandatory component of dibasic sodium phosphate monohydrate. When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1748	DIBENZYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1749	DIBUTYL ADIPATE	E	Only for use in topical medicines for dermal application.
1750	DIBUTYL PHTHALATE	E	Only for use in topical medicines for dermal application.
1751	DIBUTYL SEBACATE	E	
1752	DIBUTYLAMINE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
1753	DICAPRYLYL CARBONATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 34%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1754	DICAPRYLYL ETHER	E	Only for use in topical medicines for dermal application.
1755	DICAPRYLYL MALEATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
1756	DICETYL PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
1757	DICHLOROBENZYL ALCOHOL	E	
1758	DICHLOROMETHANE	E	The concentration in the medicine must be no more than 0.06%. The residual solvent limit for Dichloromethane is 6 mg per recommended daily dose.
1759	DICTAMNUS ALBUS	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1760	DICTAMNUS DESYCARPUS	A, H	
1761	DICYCLOHEXYL DISULFIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1762	DIEFFENBACHIA SEGUINE	H	Only for use as an active homoeopathic ingredient.
1763	DIETHANOLAMINE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 5%.
1764	DIETHYL CITRACONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1765	DIETHYL MALONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1766	DIETHYL PHTHALATE	E	
1767	DIETHYLAMINE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1768	DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1769	DIETHYLAMINOMETHYLCOUMARIN	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.1%.
1770	DIETHYLDIMETHYL-2-CYCLOHEXENONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1771	DIETHYLENE GLYCOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1772	DIETHYLENE GLYCOL MONOETHYL ETHER	E	Only for use in topical medicines for dermal application.
1773	DIETHYLHEXYL CARBONATE	E	Only for use in topical medicines for dermal application and not be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 3%.
1774	DIETHYLHEXYL SEBACATE	E	Only for use in topical medicines for dermal application.
1775	DIETHYLHEXYL SYRINGYLIDENEMALONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1776	DIETHYLHEXYL-2,6-NAPHTHALATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%. The medicine requires the following warning statement on the medicine label: - (EYE2) 'May be irritant to the eyes' (or words to that effect).
1777	DIETHYLTOLUAMIDE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 20%. The medicine requires the following warning statement on the medicine label: - (DEET) 'WARNING: May be dangerous; particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.'
1778	DIGITALIS LEAF DRY	A, H	The concentration of Digitalis leaf dry in the product must be no more

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			than 10mg/Kg or 10mg/L or 0.001%.
1779	DIGITALIS LEAF POWDER	A, H	The concentration of Digitalis leaf powder in the product must be no more than 10mg/Kg or 10mg/L or 0.001%.
1780	DIGITALIS PURPUREA	A, H	The concentration of equivalent dry Digitalis purpurea in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
1781	DIGLYCOL/CHDM/ISOPHTHALATES/SIP COPOLYMER	E	Only for use in topical medicines for dermal application.
1782	DIHEXYL FUMARATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1783	DIHYDRO JASMONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			medicine must be no more than 1%.
1784	DIHYDRO TERPINYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1785	DIHYDRO-ALPHA-TERPINEOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1786	DIHYDRO-BETA-IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1787	DIHYDRO-ISOJASMONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1788	DIHYDROACTINIDIOLIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1789	DIHYDROAMBRETTOLIDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1790	DIHYDROCARVYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1791	DIHYDROCOUMARIN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1792	DIHYDROCUMINYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
1793	DIHYDROEUGENOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1794	DIHYDROGENATED TALLOW PHTHALIC ACID AMIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			use in the eye. The concentration in the medicine must be no more than 5%.
1795	DIHYDROINDENYL-2,4-DIOXANE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1796	DIHYDROLINALOOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1797	DIHYDROMYRCENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1798	DIHYDROMYRCENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1799	DIHYDROXYACETONE	E	Only for use in topical medicines for dermal application.
1800	DIISOPROPYL ADIPATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 15%.
1801	DIISOPROPYL SEBACATE	E	Only for use in topical medicines for dermal application and not be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
1802	DIISOSTEARYL DIMER DILINOLEATE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1803	DILAURYL THIODIPROPIONATE	E	Only for use in topical medicines for dermal application.
1804	DILL HERB OIL	A, E, H	
1805	DILL SEED OIL	A, E, H	
1806	DILL WEED OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1807	DIMER DISTEARYLTRICARBONATE	E	Only for use in topical medicines for dermal application and not to be used in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
1808	DIMETHICONE 12500	E	
1809	DIMETHICONE 4000	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			must be no more than 3%.
1810	DIMETHICONE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 15%.
1811	DIMETHICONE SILYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
1812	DIMETHICONE/METHICONE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
1813	DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			must be no more than 1.5%.
1814	DIMETHYL 3-CYCLOHEXENE-1-CARBOXALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1815	DIMETHYL ANTHRANILATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1816	DIMETHYL BENZYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
1817	DIMETHYL BENZYL CARBINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1818	DIMETHYL BENZYL CARBINYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1819	DIMETHYL BENZYL CARBINYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1820	DIMETHYL PHENYLETHYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1821	DIMETHYL PHTHALATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1822	DIMETHYL POLYSILOXANE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1823	DIMETHYL SUCCINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1824	DIMETHYL SULFATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1825	DIMETHYL SULFIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1826	DIMETHYL SULFONE	A	Only for use in oral and topical medicines.
1827	DIMETHYL SULFOXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1828	DIMETHYLACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1829	DIMETHYLCYCLOHEXYLETHOXY ISOBUTYLPROPANOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1830	DIMETHYLGLYCINE HYDROCHLORIDE	A	Only for use in oral medicines.
1831	DIMETHYLOL DIMETHYL HYDANTOIN	E	Only for use in topical medicines for dermal application.
1832	DIMETICONE 1.5	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10%.
1833	DIMETICONE 10	E	
1834	DIMETICONE 100	E	Only for use in topical medicines

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			for dermal application.
1835	DIMETICONE 1000	E	
1836	DIMETICONE 1510	E	Permitted for use only in combination with other permitted ingredients as a printing ink. If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%
1837	DIMETICONE 2	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 2.5%.
1838	DIMETICONE 20	E	Only for use in topical medicines for dermal application.
1839	DIMETICONE 200	E	Only for use in topical medicines for dermal application.
1840	DIMETICONE 30	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 4%.
1841	DIMETICONE 350	E	Only for use in topical and oral medicines. When used orally, the maximum daily dose must be no more than 7.5mg.
1842	DIMETICONE 360	E	Only for use in topical medicines for dermal application.
1843	DIMETICONE 450	E	Only for use in topical medicines for dermal application.
1844	DIMETICONE 5	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10%.
1845	DIMETICONE 50	E	Only for use in topical medicines for dermal application.
1846	DIMETICONE 5000	E	Only for use in topical medicines for dermal application.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1847	DIMETICONE 6	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
1848	DIMETICONE COPOLYOL	E	Only for use in topical medicines for dermal application.
1849	DIMETICONE COPOLYOL PHOSPHATE	E	Only for use in topical medicines for dermal application.
1850	DIMETICONE CROSSPOLYMER-3	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 15%.
1851	DIMETICONE/PEG-10/15 CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1852	DIMETICONOL	E	Only for use in topical medicines for dermal application.
1853	DIMETICONOL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.
1854	DIMOCARPUS LONGAN	A, H	
1855	DIOCTYL ADIPATE	E	Only for use in topical medicines for dermal application.
1856	DIOCTYL MALEATE	E	Only for use in topical medicines for dermal application.
1857	DIOCTYL SUCCINATE	E	Only for use in topical medicines for dermal application.
1858	DIOCTYL TEREPHTHALATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1859	DIOLAMINE C8-18 PERFLUOROALKYLETHYL PHOSPHATE	E	Only for use in topical medicines for dermal application and not be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.7%
1860	DIOLAMINE CETYL PHOSPHATE	E	Only for use in topical medicines for dermal application and not be included in topical medicines intended for use in the eye.
1861	DIOSCOREA COLLETTII	A, H	
1862	DIOSCOREA COLLETTII VAR. HYPOGLAUCA	A, H	
1863	DIOSCOREA JAPONICA	A, H	
1864	DIOSCOREA OPPOSITIFOLIA	A, H	
1865	DIOSCOREA POLYSTACHYA	A, H	
1866	DIOSCOREA SEPTEMLOBA	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1867	DIOSCOREA VILLOSA	A, E, H	
1868	DIOSPYROS KAKI	A, E, H	
1869	DIOXYBENZONE	A	Only for use as an active ingredient in sunscreens for dermal application. The concentration in the medicine must be no more than 3%. When used in primary sunscreen products, the medicine requires the following warning statements on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1870	DIPENTAERYTHRITYL HEXACAPRYLATE/HEXACAPRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin. The concentration in the medicine must be no more than 0.5%.
1871	DIPENTAERYTHRITYL TETRAHYDROXYSTEARATE/TE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
	TRAISOSTEARATE		use in the eye. The concentration in the medicine must be no more than 5%.
1872	DIPENTAERYTHRITYL TRI-POLYHYDROXYSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.
1873	DIPHENYL DIMETHICONE	E	Only for use in topical medicines for dermal application.
1874	DIPHENYL METHANE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1875	DIPHENYL OXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1876	DIPOTASSIUM GLYCYRRHIZATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
1877	DIPROPIONYL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1878	DIPROPYLENE GLYCOL	E	Only for use in topical medicines for dermal application.
1879	DIPROPYLENE GLYCOL DIBENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			must be no more than 4.2%.
1880	DIPROPYLENE GLYCOL SALICYLATE	E	Only for use in topical medicines for dermal application.
1881	DIPSACUS ASPER	A, H	
1882	DIPSACUS JAPONICUS	A, H	
1883	DIPTERYX ODORATA	A, E, H	When used as an active ingredient coumarin is a mandatory component of Dipteryx odorata and the maximum daily dose of the medicine must contain no more than 0.001% of coumarin.
1884	DISODIUM ASCORBYL SULFATE	E	Only for use in topical medicines for dermal application.
1885	DISODIUM COCOAMPHODIACETATE	E	Only for use in topical medicines for dermal application.
1886	DISODIUM COCOAMPHODIPROPIONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1887	DISODIUM DIMETICONE COPOLYOL SULFOSUCCINATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 14%.
1888	DISODIUM EDETATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
1889	DISODIUM ETHYLENE DICOCAMIDE PEG-15 DISULFATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1%.
1890	DISODIUM GUANYLATE	E	Permitted for use only in combination with other permitted

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1891	DISODIUM INOSINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1892	DISODIUM LAURIMINODIPROPIONATE TOCOPHERYL PHOSPHATES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
1893	DISODIUM NADH	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.02%.
1894	DISODIUM OLEAMIDO PEG-2 SULFOSUCCINATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			eye. The concentration in the medicine must be no more than 1%.
1895	DISODIUM PHENYL DIBENZIMIDAZOLE TETRASULFONATE	A	Only for use as an active ingredient in sunscreens for dermal application. The concentration in the medicine must be no more than 10%. When used in primary sunscreen products, the medicine requires the following warning statements on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1896	DISODIUM RICINOLEAMIDO MEA-SULFOSUCCINATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1897	DISODIUM RUTINYL DISULFATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.05%.
1898	DISODIUM STEAROYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
1899	DISPERSIBLE CELLULOSE	E	
1900	DISTARCH PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
1901	DISTEARDIMONIUM HECTORITE	E	Only for use in topical medicines for dermal application and not to be included for medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
1902	DISTEARETH-6 DIMONIUM CHLORIDE	E	Only for use in topical medicines for dermal application.
1903	DISTEARYL PHTHALIC ACID AMIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
1904	DISTEARYLDIMONIUM CHLORIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
1905	DIVINYLDIMETHICONE/DIMETHICONE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.5%.
1906	DL-ALPHA-TOCOPHEROL	A, E	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1907	DL-ALPHA-TOCOPHERYL ACETATE	A, E, H	
1908	DL-ALPHA-TOCOPHERYL ACID SUCCINATE	A, E, H	
1909	DL-BORNEOL	E	
1910	DL-LIMONENE	E	Only for use in topical medicines for dermal application.
1911	DL-THREONINE	A, E	
1912	DOCOSAHEXAENOIC ACID (DHA)-RICH OIL DERIVED FROM MICROALGAE SCHIZOCHYTRIUM SP.	A	Only for use in oral medicines and must be present in combination with other ingredients.
1913	DOCUSATE SODIUM	E	
1914	DODECAHYDRO-3A,6,6,9A-TETRAMETHYLNAPHTHO(2,1-B)FURAN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1915	DODECANENITRILE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			medicine must be no more than 1%.
1916	DODECENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1917	DODECENE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.2%.
1918	DODECYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1919	DODECYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1920	DOLICHOS LABLAB	A, H	
1921	DOLOMITE	A, E, H	
1922	DRACAENA DRACO	A, H	
1923	DRIED BUTTERMILK	E	
1924	DRIED CALCIUM SULFATE	A, E, H	
1925	DRIED MAGNESIUM SULFATE	A, E, H	When used internally, the maximum recommended daily dose must be no more than 1.5g.
1926	DRIMIA INDICA	A, H	
1927	DRIMIA MARITIMA	A, H	
1928	DROMETRIZOLE TRISILOXANE	A	Only for use as an active ingredient in sunscreens for dermal application. The concentration in a medicine must be no more than 10%. When used in primary sunscreen products, the medicine requires the following warning statements on

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1929	DROSERA ANGLICA	A, H	
1930	DROSERA BURMANNI	A, H	
1931	DROSERA INTERMEDIA	A, H	
1932	DROSERA RAMENTACIA	A, H	
1933	DROSERA ROTUNDIFOLIA	A, E, H	
1934	DROSERA ROTUNDIFOLIA MIS	A, H	
1935	DRYNARIA FORTUNEI	A, H	
1936	DRYOBALANOPS AROMATICA	A, H	
1937	DRYOPTERIS FILIX-MAS	H	Only for use as an active homoeopathic ingredient.
1938	DULACIA INOPIFLORA	A, H	
1939	DUNALIELLA SALINA	A, E, H	
1940	DUPICAL	E	Permitted for use only in combination with other permitted

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1941	DURVILLAEA ANTARCTICA EXTRACT	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.1%.
1942	DWARF PINE-NEEDLE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
1943	DYSPHANIA AMBROSIOIDES	A, H	Volatile oil components (of Dysphania ambrosioides) are mandatory components of Dysphania ambrosioides.
1944	ECAMSULE	A	Only for use as an active ingredient in sunscreens for dermal

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			application. The concentration in the medicine must be no more than 10%. When used in primary sunscreen products, the medicine requires the following warning statements on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
1945	ECHINACEA ANGUSTIFOLIA	A, E, H	
1946	ECHINACEA PALLIDA	A, E, H	
1947	ECHINACEA PURPUREA	A, E, H	
1948	ECHINOPA SPINOSISSIMUS	A, H	
1949	ECLIPTA PROSTRATA	A, H	
1950	ECTOIN	E	Only for use as an excipient ingredient in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
1951	EDETATE SODIUM	E	Only for use in topical medicines for dermal application and nasal medicines. The concentration in the medicine must be no more than 0.2%.
1952	EDETIC ACID	E	The concentration in the medicine must be no more than 0.25%.
1953	EGG LECITHIN	A, E	
1954	EGGSHELL MEMBRANE HYDROLYSATE	A	
1955	EGGSHELL MEMBRANE POWDER	A	
1956	EICHHORNIA CRASSIPES	A, H	
1957	ELAEAGNUS ANGUSTIFOLIA	A, H	
1958	ELAEIS GUINEENSIS	A, E, H	
1959	ELASTIN	E	Only for use in topical medicines for dermal application.
1960	ELDER FLOWER ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
1961	ELDER FLOWER BLACK DRY	A, E, H	
1962	ELDER FLOWER BLACK POWDER	A, H	
1963	ELECAMPANE RHIZOME DRY	A, H	
1964	ELECAMPANE RHIZOME POWDER	A, H	
1965	ELEMI OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1966	ELEMI RESINOID	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1967	ELEMOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			fragrance concentration in a medicine must be no more than 1%.
1968	ELEOCHARIS DULCIS	A, H	
1969	ELETTARIA CARDAMOMUM	A, E, H	
1970	ELEUTHEROCOCCUS NODIFLORUS	A, H	
1971	ELEUTHEROCOCCUS ROOT DRY	A, H	
1972	ELEUTHEROCOCCUS ROOT POWDER	A, H	
1973	ELEUTHEROCOCCUS SENTICOSUS	A, H	
1974	ELSHOLTZIA SPLENDENS	A, H	
1975	ELYMUS REPENS	A, E, H	
1976	EMU OIL	A, E	Emu oil ingredients must meet the following two requirements: 1) the manufacturing process is to include steps such as cooking, fat drying or deodorising which ensures the temperature of the oil reaches at least 60 degrees C for a minimum 5 minutes or at least 100 degrees C for a minimum of 1 minute, and 2) the sponsor is to hold a veterinary certificate indicating that the emus from which the raw

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			material was extracted were healthy and fit for human consumption.
1977	EMULSIFYING WAX	E	
1978	ENOXOLONE	E	Only for use in topical medicines for dermal application.
1979	ENZYME MODIFIED CREAM	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
1980	EPHEDRA DISTACHYA	A, H	Ephedrine and Pseudoephedrine (of Ephedra distachya) are mandatory components of Ephedra distachya and must be declared in the application. The concentration of ephedrine from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
1981	EPHEDRA SINICA	A, H	Ephedrine and Pseudoephedrine (of Ephedra sinica) are mandatory components of Ephedra sinica. The concentration of ephedrine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
1982	EPIGAEA REPENS	A, H	
1983	EPILOBIUM ANGUSTIFOLIUM	E	Only for use in topical sunscreens for dermal application and not to be included in medicines intended for use in the eye. The extract must be processed from the flower, leaf and stem (herb top flowering) of the plant. The extracts used must be: 1:20 in 100% water or 1:2 in 100% water. The concentrations of Epilobium angustifolium must be no more than 0.75% for a 1:2 extract in 100% water, and 5% for a 1:20 extract in 100% water.
1984	EPILOBIUM PALUSTRE	A, H	
1985	EPILOBIUM PARVIFLORUM	A, H	
1986	EPIMEDIUM BREVICORNU	A, H	
1987	EPIMEDIUM GRANDIFLORUM	A, H	
1988	EPIMEDIUM SAGITTATUM	A, H	
1989	EPOXY CEDRENE	E	Permitted for use only in combination with other permitted

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
1990	EQUISETUM ARVENSE	A, E, H	
1991	EQUISETUM HIEMALE	A, H	
1992	ERGOCALCIFEROL	A, E	When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.
1993	ERGOTHIONEINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.0005%.
1994	ERIGERON BREVISCAPUS	A, H	
1995	ERIOBOTRYA JAPONICA	A, H	Amygdalin and hydrocyanic acid are mandatory components. The concentration of amygdalin in the medicine must be 0%. The concentration of hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			microgram/L or 0.0000001%.
1996	ERIOCAULON BUERGERIANUM	A, H	
1997	ERIODICTYON CRASSIFOLIUM	A, H	
1998	ERIODICTYON GLUTINOSUM	A, H	
1999	ERODIUM CICUTARIUM	A, H	
2000	ERUCA SATIVA	A, H	
2001	ERYTHORBIC ACID	E	
2002	ERYTHRITOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2003	ERYTHROSINE	E	Only for use as a colour for oral and topical use.
2004	ERYTHROSINE ALUMINIUM LAKE	E	Only for use as a colour for oral and topical use.
2005	ERYTHRULOSE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 2%. The medicine requires the following warning statement on the medicine label: - (EYE) 'Avoid contact with eyes'.
2006	ESCHSCHOLZIA CALIFORNICA	A, H	
2007	ESTRONE	H	Only for use as an active homoeopathic ingredient.
2008	ETHANOL	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. When the concentration of ethanol from all ingredients in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol or contains alcohol'.
2009	ETHANOL ABSOLUTE	A, E	When used as an active ingredient, can only be supplied as an

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. When the concentration of ethanol from all ingredients in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol or contains alcohol'
2010	ETHER	E	The concentration of ether in the medicine must be no more than 10%.
2011	ETHOHEXADIOL	E	Only for use in topical medicines for dermal application. The medicine requires the following warning statement on the medicine label: - (EHEXAD) 'Contains ethohexadiol' (or words to that effect).
2012	ETHOXYLATED HYDROGENATED CASTOR OIL	E	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2013	ETHOXYLATED NONYLPHENOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2014	ETHOXYMETHOXY CYCLODODECANE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2015	ETHYL (2,4-DIMETHYL-[1,3] DIOXOLAN-2-YL) ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2016	ETHYL (3AR,4S,7R,7AR)-REL-OCTAHYDRO-4,7-METHANO[3AH]INDENE-3A-CARBOXYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more than 1%.
2017	ETHYL 2,3,6,6-TETRAMETHYL-2-CYCLOHEXENECARBOXYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2018	ETHYL 2,6,6,TRIMETHYL-1,3-CYCLOHEXADIENE-1-CARBOXYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2019	ETHYL 2-BUTENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2020	ETHYL 2-ETHYL-6,6-DIMETHYL-2-CYCLOHEXENECARBOXYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more than 1%.
2021	ETHYL 2-HEXYL ACETOACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2022	ETHYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2023	ETHYL 2-METHYLPENTANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
2024	ETHYL 3-HEXENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2025	ETHYL 3-HYDROXYBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2026	ETHYL 3-HYDROXYHEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2027	ETHYL 3-MERCAPTOPROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
2028	ETHYL 3-METHYLTHIOPROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2029	ETHYL 4,7-OCTADIENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2030	ETHYL ACETATE	E	The residual solvent limit for ethyl acetate is 50 mg per recommended daily dose. The concentration in the medicine must be no more than 0.5%.
2031	ETHYL ACETOACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2032	ETHYL ACRYLATE	E	
2033	ETHYL AMYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2034	ETHYL ANTHRANILATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2035	ETHYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2036	ETHYL BENZOYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2037	ETHYL BUTYLACETYLAMINOPROPIONATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 7.5%. The medicine requires the following warning statement on the medicine label: - (EYE2) 'May be irritant to the eyes (or words to that effect)'.
2038	ETHYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2039	ETHYL CAPRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2040	ETHYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
2041	ETHYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2042	ETHYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2043	ETHYL CROTONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2044	ETHYL ENANTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2045	ETHYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2046	ETHYL HYDROXYBENZOATE	E	Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
2047	ETHYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2048	ETHYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2049	ETHYL LACTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2050	ETHYL LAURATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2051	ETHYL LEVULATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2052	ETHYL LEVULINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2053	ETHYL LINALOOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2054	ETHYL LINALYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2055	ETHYL LINOLEATE	E	Only for use in topical medicines for dermal application.
2056	ETHYL LINOLENATE	E	Only for use in topical medicines for dermal application.
2057	ETHYL MACADAMIATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2058	ETHYL MALTOL	E	
2059	ETHYL MENTHANE CARBOXAMIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2060	ETHYL METHACRYLATE	E	Only for use in topical medicines for dermal application.
2061	ETHYL METHYLPHENYLGLYCIDATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2062	ETHYL METICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
2063	ETHYL MYRISTATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2064	ETHYL OLEATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2065	ETHYL ORTHO-METHOXYBENZYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
2066	ETHYL OXYHYDRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2067	ETHYL PALMITATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2068	ETHYL PARA-ANISATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	**Column 2** **Ingredient Name**	**Column 3** **Purpose of the ingredient in the medicine**	**Column 4** **Specific requirement(s) applying to the ingredient in Column 2**
2069	ETHYL PELARGONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2070	ETHYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2071	ETHYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2072	ETHYL RICINOLEATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2073	ETHYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2074	ETHYL SEBACATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			no more than 5%.
2075	ETHYL STEARATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2076	ETHYL SUCCINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2077	ETHYL TARTRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2078	ETHYL TRANS-2, CIS-4-DECADIENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			concentration in a medicine must be no more than 5%.
2079	ETHYL TRANS-3-HEXENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2080	ETHYL UNDECYLENATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2081	ETHYL VALERATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2082	ETHYL VANILLIN	E	
2083	ETHYL-2-METHYL-1,3-DIOXOLANE-2-ACETATE	E	Permitted for use only in combination with other permitted

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2084	ETHYL-2-METHYL-4-PENTENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2085	ETHYL-2-METHYLPENTENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2086	ETHYLBISIMINOMETHYL GUAIACOL MANGANESE CHLORIDE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.002%.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2087	ETHYLCELLULOSE	E	
2088	ETHYLENE BRASSYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2089	ETHYLENE GLYCOL	E	The residual solvent limit for ethylene glycol is 6.2 mg per recommended daily dose. The concentration in the medicine must be no more than 0.062%.
2090	ETHYLENE GLYCOL MONOPALMITOSTEARATE	E	Only for use in topical medicines for dermal application.
2091	ETHYLENE/ACRYLIC ACID COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
2092	ETHYLENE/VINYL ACETATE	E	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
	COPOLYMER		included in medicines intended for use in the eye. The concentration in the medicine must be no more than 16%.
2093	ETHYLENEDIAMINE	E	Only for use in topical medicines for dermal application.
2094	ETHYLENEDIAMINE/HYDROGENATED DIMER DILINOLEATE COPOLYMER BIS-DI-C14-18 ALKYL AMIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
2095	ETHYLENEDIAMINE/STEARYL DIMER DILINOLEATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 6%.
2096	ETHYLHEXYL BENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			must be no more than 3.5%.
2097	ETHYLHEXYL METHOXYCRYLENE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
2098	ETHYLHEXYL TRIAZONE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2099	ETHYLHEXYLGLYCERIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2100	ETIDRONIC ACID	E	Only for use in topical medicines for dermal application only. The concentration in the medicine must be no more than 1%.
2101	EUCALYPTUS DIVES	A, E, H	Cineole is a mandatory component of Eucalyptus dives. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2102	EUCALYPTUS FRUTICETORUM	A, E, H	Cineole is a mandatory component of Eucalyptus fruticetorum. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2103	EUCALYPTUS GLOBULUS	A, E, H	Cineole is a mandatory component of Eucalyptus globulus. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres;

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2104	EUCALYPTUS MACRORHYNCHA	A, E, H	Cineole is a mandatory component of Eucalyptus macrorhyncha. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2105	EUCALYPTUS OIL	A, E, H	Cineole is a mandatory component of Eucalyptus oil. When the plant preparation is oil and the total concentration of the oil in the preparation is more than 25%, the nominal capacity of the container must be no more than 25 mL. When the plant preparation is oil and the total concentration of the oil in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL but no more than 25mL, a child resistant closure and restricted flow

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			insert must be fitted on the container. The medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' When the concentration of the oil in the preparation is more than 25% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert must be fitted on the container. The medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken'
2106	EUCALYPTUS RADIATA	A, E, H	Cineole is a mandatory component of Eucalyptus radiata. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2107	EUCALYPTUS ROSTRATA	A, E, H	Cineole is a mandatory component of Eucalyptus rostrata. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2108	EUCALYPTUS TERETICORNIS	A, E, H	Cineole is a mandatory component of Eucalyptus tereticornis. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label:

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
2109	EUCOMMIA ULMOIDES	A, H	
2110	EUGENOL	E	When for oral ingestion, eugenol must not comprise more than 0.06% of the formulation. When used in topical medicines for dermal application, the following apply: a) When the concentration of Eugenol in the preparation is more than 25%, the nominal capacity of the container must be no more than 25 mL. b) When the concentration of Eugenol in the preparation is more than 25% and the nominal capacity of the container is more than 15 mL but no more than 25mL, a child

Column 1	Column 2 **Ingredient Name**	Column 3 **Purpose of the ingredient in the medicine**	Column 4 **Specific requirement(s) applying to the ingredient in Column 2**
			resistant closure and restricted flow insert must be fitted on the container. The medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken' c) When the concentration of Eugenol in the preparation is more than 25% and the nominal capacity of the container is no more than 15mL, a restricted flow insert must be fitted on the container. The medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect) - (NTAKEN) 'Not to be taken'
2111	EUGENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
2112	EUONYMUS ATROPURPUREUS	A, H	
2113	EUONYMUS EUROPAEUS	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
2114	EUPATORIUM FORTUNEI	A, H	
2115	EUPATORIUM JAPONICUM	A, H	
2116	EUPATORIUM PERFOLIATUM	A, H	
2117	EUPATORIUM PURPUREUM	A, H	
2118	EUPHAUSIA SUPERBA OIL	A	Only for use in oral medicines. The medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood' or - (SHELL) 'Contains crustacean shellfish'.
2119	EUPHORBIA CYPARISSIAS	A, H	
2120	EUPHORBIA DRY	A, H	

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2121	EUPHORBIA HETERODOXA	A, H	
2122	EUPHORBIA HIRTA	A, H	
2123	EUPHORBIA LATHYRIS	A, H	Levodopa (of Euphorbia lathyris) is a mandatory component of Euphorbia lathyris. The concentration of Levodopa (of Euphorbia lathyris) in the medicine must be no more than 10mg/kg or 10mg/L or 0.001%.
2124	EUPHORBIA PEKINENSIS	A, H	
2125	EUPHORBIA PEPLUS	H	Only for use as an active homoeopathic ingredient.
2126	EUPHORBIA POWDER	A, H	
2127	EUPHORBIA RESINIFERA	A, H	
2128	EUPHORBIA SIEBOLDIANA	A, H	
2129	EUPHRASIA OFFICINALIS	A, H	
2130	EUROPEAN GARDEN SPIDER	H	Only for use as an active homoeopathic ingredient.
2131	EUROPEAN HORNET	H	Only for use as an active homoeopathic ingredient.

Column 1	Column 2 Ingredient Name	Column 3 Purpose of the ingredient in the medicine	Column 4 Specific requirement(s) applying to the ingredient in Column 2
2132	EURYALE FEROX	A, H	
2133	EUTERPE OLERACEA	A	The herbal substance must be derived from the fruit only.
2134	EVENING PRIMROSE OIL	A, E, H	
2135	EVERNIA PRUNASTRA EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.